PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10548268-6 1999 The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice. Pargyline 35-44 monoamine oxidase B Mus musculus 17-22 10320000-1 1999 The present study investigated in vivo the kinetic of the changes in rat striatal extracellular concentrations of dopamine (DA), and its monoamine oxidase (MAO)-derived metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), following administration either of nitric oxide (NO) synthase (NOS) inhibitors 7-nitroindazole (7-NI) and Nomega-nitro-l-arginine methyl ester (L-NAME) or of the widely used MAO inhibitor pargyline. Pargyline 408-417 monoamine oxidase A Rattus norvegicus 156-159 10064798-3 1999 Adrenaline levels were undetectable in the PCG but to test the hypothesis that PNMT is active in SIF cells, catecholamines were measured in ganglia of rats pretreated with pargyline, an inhibitor of the monoamine oxidase, the major enzyme involved in the catecholamine degradation. Pargyline 172-181 phenylethanolamine-N-methyltransferase Rattus norvegicus 79-83 10208305-3 1999 For this purpose, the locus coeruleus was superfused in the absence and in the presence of the MAO inhibitor pargyline. Pargyline 109-118 monoamine oxidase A Rattus norvegicus 95-98 10208295-8 1999 After the acute administration of both deprenyl and pargyline, a significant decrease in the MAO activities of both young (P=0.0002 for each) and aging rats (P=0.0002 for deprenyl and P=0.0001 for pargyline) were observed. Pargyline 52-61 monoamine oxidase A Rattus norvegicus 93-96 10208295-8 1999 After the acute administration of both deprenyl and pargyline, a significant decrease in the MAO activities of both young (P=0.0002 for each) and aging rats (P=0.0002 for deprenyl and P=0.0001 for pargyline) were observed. Pargyline 197-206 monoamine oxidase A Rattus norvegicus 93-96 10025842-6 1999 In the first approach, oxidation of PHEN by MAO was inhibited at the enzymatic level with the MAO inhibitor pargyline. Pargyline 108-117 monoamine oxidase A Rattus norvegicus 44-47 10081977-1 1999 The present study investigated in vivo the kinetics of the changes in rat striatal extracellular concentrations of dopamine (DA), and its monoamine oxidase (MAO)-derived metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), following administration either of nitric oxide (NO) synthase inhibitors 7-nitroindazole (7-NI) and N(omega)-nitro-L-arginine methyl ester (L-NAME) or of the widely used MAO inhibitor pargyline. Pargyline 405-414 monoamine oxidase A Rattus norvegicus 157-160 10025842-6 1999 In the first approach, oxidation of PHEN by MAO was inhibited at the enzymatic level with the MAO inhibitor pargyline. Pargyline 108-117 monoamine oxidase A Rattus norvegicus 94-97 10025842-10 1999 Inhibition of MAO activity with either pargyline or di-deuterium substitution did not significantly alter this rate. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 14-17 9564606-0 1998 Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). Pargyline 131-140 monoamine oxidase B Homo sapiens 109-114 9754903-8 1998 There were no signs of depletion of dopaminergic cells or glial activation after the administration of MPTP simultaneously with pargyline, an inhibitor of monoamine oxidase-B that prevents MPTP neurotoxicity. Pargyline 128-137 monoamine oxidase B Mus musculus 155-174 9933502-2 1999 Intraperitoneal injection of IL-1beta increased the turnover rate of hypothalamic HA, which was assessed by accumulation of tele-methylhistamine after pargyline treatment. Pargyline 151-160 interleukin 1 beta Rattus norvegicus 29-37 9813295-7 1998 Systemic monoamine oxidase-B inhibitor pargyline delayed the peak and return to baseline of endogenously produced MPP+ in the nucleus accumbens. Pargyline 39-48 monoamine oxidase B Rattus norvegicus 9-28 9564606-2 1998 In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90 mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Pargyline 86-95 monoamine oxidase B Homo sapiens 100-105 9564606-2 1998 In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90 mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Pargyline 86-95 monoamine oxidase A Homo sapiens 111-116 9771127-1 1998 The active immunization of albino rats against pargyline (a MAO B inhibitor) induced the formation of antibody to pargyline and results in deep depressive changes and fear. Pargyline 47-56 monoamine oxidase B Rattus norvegicus 60-65 9771127-1 1998 The active immunization of albino rats against pargyline (a MAO B inhibitor) induced the formation of antibody to pargyline and results in deep depressive changes and fear. Pargyline 114-123 monoamine oxidase B Rattus norvegicus 60-65 9324239-2 1997 The influence of isatin on the degree of irreversible MAO inhibition by phenelzine and pargyline has been studied in vitro and in vivo experiments. Pargyline 87-96 monoamine oxidase A Rattus norvegicus 54-57 9503561-4 1997 MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline. Pargyline 251-260 monoamine oxidase A Homo sapiens 0-5 9503561-4 1997 MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline. Pargyline 251-260 monoamine oxidase B Homo sapiens 110-115 8780041-6 1996 Moreover, cerebrocortical NPY-ir was reduced in rats receiving treatment with pargyline, an inhibitor of monoamine oxidase, with an elevation of catecholamine in parallel. Pargyline 78-87 neuropeptide Y Rattus norvegicus 26-29 8945753-0 1996 Activation of alpha 1-adrenoceptors to lower cerebrocortical neuropeptide Y (NPY)-like immunoreactivity in rats receiving pargyline treatment. Pargyline 122-131 neuropeptide Y Rattus norvegicus 61-75 8945753-0 1996 Activation of alpha 1-adrenoceptors to lower cerebrocortical neuropeptide Y (NPY)-like immunoreactivity in rats receiving pargyline treatment. Pargyline 122-131 neuropeptide Y Rattus norvegicus 77-80 8945753-4 1996 Values of NPY-like immunoreactivity (NPY-ir) were reduced in rats receiving the treatment of pargyline, the inhibitor of monoamine oxidase, with an elevation of catecholamine in parallel. Pargyline 93-102 neuropeptide Y Rattus norvegicus 10-13 8945753-4 1996 Values of NPY-like immunoreactivity (NPY-ir) were reduced in rats receiving the treatment of pargyline, the inhibitor of monoamine oxidase, with an elevation of catecholamine in parallel. Pargyline 93-102 neuropeptide Y Rattus norvegicus 37-40 9273781-6 1997 Preincubation of homogenates with 0.1 mM pargyline completely inhibited monoamine oxidases A and B and prevented NADH-dependent formation of 4-hydroxyphenylethanol from tyramine. Pargyline 41-50 monoamine oxidase A Bos taurus 72-98 8912226-4 1996 The possibility that these discrepant results were due to metabolism of the receptor ligands was investigated by increasing the concentration of the monoamine oxidase (MAO) inhibitor, pargyline. Pargyline 184-193 monoamine oxidase A Rattus norvegicus 149-166 8912226-4 1996 The possibility that these discrepant results were due to metabolism of the receptor ligands was investigated by increasing the concentration of the monoamine oxidase (MAO) inhibitor, pargyline. Pargyline 184-193 monoamine oxidase A Rattus norvegicus 168-171 8813364-3 1996 In L-DOPA/carbidopa-injected rats that were pretreated with an intraperitoneal injection of a MAO inhibitor, pargyline, when compared with the L-DOPA/carbidopa-injected rats without the pargyline pretreatment, neurons of the cluster of the DR became much darker in dopamine staining. Pargyline 109-118 monoamine oxidase A Rattus norvegicus 94-97 8717160-3 1996 MAO and COMT were inhibited by treatment with pargyline (40 mg/kg) and tolcapone (3 mg/kg followed by 1.5 mg/kg given every 30 min), respectively. Pargyline 46-55 catechol O-methyltransferase Oryctolagus cuniculus 8-12 8820177-3 1996 As expected, after pargyline administration tissue concentrations of 5-HT, noradrenaline (NA) and dopamine (DA) were markedly increased due to MAO inhibition with a concomitant decrease of the metabolites 5-hydroxyindole-3-acetic acid and homovanillic acid. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 143-146 8852930-4 1996 The inhibitory effect of monoamine oxidase (MAO) activity by pargyline was maximal at 1.5 months. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 25-42 8852930-4 1996 The inhibitory effect of monoamine oxidase (MAO) activity by pargyline was maximal at 1.5 months. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 44-47 8821542-4 1996 COMT activity, evaluated by the ability to methylate adrenaline to metanephrine, was determined in liver and kidney homogenates prepared in 0.5 mM phosphate buffer (pH = 7.8) containing pargyline (0.1 mM), MgCl2 (0.1 mM), EGTA (1 mM) and S-adenosyl-L-methionine (0.1 mM). Pargyline 186-195 catechol-O-methyltransferase Rattus norvegicus 0-4 8821544-2 1996 2 The non-specific MAO inhibitor, pargyline, superfused at a concentration of 10-100 microM, decreased or abolished the spontaneous firing discharge of the principal neurons in the subtantia nigra pars compacta and ventral tegmental area. Pargyline 34-43 monoamine oxidase A Rattus norvegicus 19-22 9101254-9 1995 The oxidant scavenger dimethylthiourea (DMTU) and the monoamine oxidase (MAO) inhibitor pargyline, administered to CO poisoned rats after HBO at 2.5 ATA, diminished 2,3-DHBA production in both subcellular compartments. Pargyline 88-97 monoamine oxidase A Rattus norvegicus 54-71 8535333-3 1995 We have developed an iodinated derivative of pargyline, a selective inhibitor of MAO B, in order to explore this enzyme by SPECT. Pargyline 45-54 monoamine oxidase B Rattus norvegicus 81-86 8535333-9 1995 2-iodopargyline has a higher in vitro affinity for MAO B than pargyline. Pargyline 6-15 monoamine oxidase B Rattus norvegicus 51-56 8535333-10 1995 However, the in vitro selectivity for MAO B was better for pargyline than for 2-iodopargyline. Pargyline 59-68 monoamine oxidase B Rattus norvegicus 38-43 7720101-12 1995 FMO1 and FMO3, expressed in either system, displayed product stereoselectivity in their catalysis of the N-oxidation of the pro-chiral tertiary amines, N-ethyl-N-methylaniline (EMA) and pargyline. Pargyline 186-195 flavin containing dimethylaniline monoxygenase 1 Homo sapiens 0-4 7720101-12 1995 FMO1 and FMO3, expressed in either system, displayed product stereoselectivity in their catalysis of the N-oxidation of the pro-chiral tertiary amines, N-ethyl-N-methylaniline (EMA) and pargyline. Pargyline 186-195 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 9-13 7720101-14 1995 But in the case of pargyline, the enzymes displayed opposite stereoselectivity, FMO1 producing solely the (+)-enantiomer and FMO3 predominantly the (-)-enantiomer of the N-oxide. Pargyline 19-28 flavin containing dimethylaniline monoxygenase 1 Homo sapiens 80-84 7720101-14 1995 But in the case of pargyline, the enzymes displayed opposite stereoselectivity, FMO1 producing solely the (+)-enantiomer and FMO3 predominantly the (-)-enantiomer of the N-oxide. Pargyline 19-28 flavin containing dimethylaniline monoxygenase 3 Homo sapiens 125-129 11224327-5 1995 Chronic administration (two injections/day for 8 weeks) with a non-selective (i.e. MAO-A and MAO-B inhibiting) dose of pargyline (15mg/kg) resulted in a time-dependent increase in punished responding. Pargyline 119-128 monoamine oxidase A Rattus norvegicus 83-88 11224327-5 1995 Chronic administration (two injections/day for 8 weeks) with a non-selective (i.e. MAO-A and MAO-B inhibiting) dose of pargyline (15mg/kg) resulted in a time-dependent increase in punished responding. Pargyline 119-128 monoamine oxidase B Rattus norvegicus 93-98 11224327-6 1995 In contrast, chronic administration of the MAO-A selective inhibitor (clorgyline; 1.0mg/kg, 2mg/kg), the MAO-B selective inhibitor deprenyl (5mg/kg) or MAO-B inhibiting doses of pargyline (1.0mg/kg, 5mg/kg) were without effect. Pargyline 178-187 monoamine oxidase B Rattus norvegicus 152-157 8577805-0 1995 5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats. Pargyline 83-92 5-hydroxytryptamine receptor 1A Rattus norvegicus 0-6 8577805-8 1995 These results suggest that tryptophan-induced hypo- and hyperthermia are mediated by 5-HT1A and 5-HT2 receptors, respectively, in the pargyline-pretreated pretreated rats. Pargyline 134-143 5-hydroxytryptamine receptor 1A Rattus norvegicus 85-91 8528552-8 1995 The remaining 30-40% was displaced specifically by the monoamine oxidase A inhibitors, clorgyline and pargyline. Pargyline 102-111 monoamine oxidase A Rattus norvegicus 55-74 8868138-3 1995 In animals receiving pargyline (a MAO-A inhibitor which blocks 5-HT catabolism), AS-8 markedly enhanced 5-HT accumulation in the brains of rats and mice, but not chicks. Pargyline 21-30 monoamine oxidase A Rattus norvegicus 34-39 7478301-3 1995 In the present study, release of the false transmitter serotonin from the dopaminergic nerve terminals was studied by loading the neurons in vivo with serotonin precursor L-tryptophan and MAO inhibitor pargyline, which results in accumulation of false transmitter serotonin. Pargyline 202-211 monoamine oxidase A Rattus norvegicus 188-191 9101254-9 1995 The oxidant scavenger dimethylthiourea (DMTU) and the monoamine oxidase (MAO) inhibitor pargyline, administered to CO poisoned rats after HBO at 2.5 ATA, diminished 2,3-DHBA production in both subcellular compartments. Pargyline 88-97 monoamine oxidase A Rattus norvegicus 73-76 7829993-2 1994 Normal rats treated with clorgyline (a selective MAO-A inhibitor) or tranylcypromine (a non-selective MAO inhibitor) showed a significantly diminished thyroid MAO activity, while deprenyl and pargyline (MAO-B inhibitors) did not modify the thyroidal enzyme activity with respect to the control group. Pargyline 192-201 monoamine oxidase B Rattus norvegicus 203-208 7853182-6 1995 Moreover, [3H]-idazoxan binding was also competed for by several MAO inhibitors (MAOI) that are not imidazoline or guanidinium derivatives such as tranylcypromine, harmaline, clorgiline and pargyline. Pargyline 190-199 monoamine oxidase A Rattus norvegicus 65-68 7830076-4 1995 Furthermore, clorgyline, a selective inhibitor of monoamine oxidase type A, and pargyline, an inhibitor of both monoamine oxidase types A and B, both did not have an effect on L-DOPA toxicity. Pargyline 80-89 monoamine oxidase A Rattus norvegicus 112-143 8013556-6 1994 Inhibition of monoamine oxidase A and monoamine oxidase B with pargyline (75 mg kg-1, 2 h) significantly increased the levels of extracellular dopamine and reduced those of their acid metabolites. Pargyline 63-72 amine oxidase [flavin-containing] A Cavia porcellus 14-33 7990969-2 1994 Monoamine oxidase and catechol-O-methyl transferase were inhibited with pargyline (500 mumol/l) and Ro 01-2812 (3,5-dinitropyrocatechol; 2 mumol/l), respectively. Pargyline 72-81 catechol-O-methyltransferase Rattus norvegicus 22-51 7953696-9 1994 Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities. Pargyline 30-39 monoamine oxidase A Homo sapiens 69-74 7953696-9 1994 Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities. Pargyline 30-39 monoamine oxidase A Homo sapiens 118-123 7953696-9 1994 Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities. Pargyline 30-39 monoamine oxidase B Homo sapiens 128-133 8013556-6 1994 Inhibition of monoamine oxidase A and monoamine oxidase B with pargyline (75 mg kg-1, 2 h) significantly increased the levels of extracellular dopamine and reduced those of their acid metabolites. Pargyline 63-72 amine oxidase [flavin-containing] B Cavia porcellus 38-57 7931249-7 1994 At these doses, befloxatone inhibited totally and selectively MAO-A, pargyline inhibited totally MAO-A and MAO-B. Pargyline 69-78 monoamine oxidase A Rattus norvegicus 97-102 7931249-7 1994 At these doses, befloxatone inhibited totally and selectively MAO-A, pargyline inhibited totally MAO-A and MAO-B. Pargyline 69-78 monoamine oxidase B Rattus norvegicus 107-112 7931249-8 1994 Increases of tissue and extracellular concentrations of NA and 5HT were highest after Pargyline suggesting that both monoamines may be metabolized by MAO-A and MAO-B. Pargyline 86-95 monoamine oxidase A Rattus norvegicus 150-155 7931249-8 1994 Increases of tissue and extracellular concentrations of NA and 5HT were highest after Pargyline suggesting that both monoamines may be metabolized by MAO-A and MAO-B. Pargyline 86-95 monoamine oxidase B Rattus norvegicus 160-165 8377936-1 1993 The effect of pargyline on dopamine neurotransmission was investigated by trans-striatal microdialysis combined with Fos immunohistochemistry. Pargyline 14-23 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 117-120 8114614-6 1994 To confirm our hypothesis, the ability of pargyline to inhibit three cytochrome P-450 (P-450) isozyme-specific monooxygenase activities in vitro was studied using mouse liver microsomes. Pargyline 42-51 cytochrome P450, family 21, subfamily a, polypeptide 1 Mus musculus 69-85 8121637-2 1993 Displacement of the [3H]pargyline binding on MAO-A (L(-)-deprenyl suppressed binding to MAO-B) by harman, 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) revealed IC50 values of 250 +/- 100 nM, 3.1 +/- 0.8 microM, and 5.1 +/- 0.4 microM, respectively. Pargyline 24-33 monoamine oxidase A Rattus norvegicus 45-50 8121637-2 1993 Displacement of the [3H]pargyline binding on MAO-A (L(-)-deprenyl suppressed binding to MAO-B) by harman, 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) revealed IC50 values of 250 +/- 100 nM, 3.1 +/- 0.8 microM, and 5.1 +/- 0.4 microM, respectively. Pargyline 24-33 monoamine oxidase B Rattus norvegicus 88-93 8147263-3 1993 Addition of an MAO inhibitor such as pargyline to tissue preparations can increase the HNMT activity assayed --presumably as a result of inhibition of N tau-methylhistamine metabolism by MAO. Pargyline 37-46 histamine N-methyltransferase Homo sapiens 87-91 8147263-7 1993 The activity of the purified HNMT was increased approximately 50% in the presence of pargyline. Pargyline 85-94 histamine N-methyltransferase Homo sapiens 29-33 8147263-8 1993 However, enzyme kinetic experiments showed that pargyline, like many other amines, was a competitive inhibitor of HNMT. Pargyline 48-57 histamine N-methyltransferase Homo sapiens 114-118 8147263-12 1993 When the concentration of the cosubstrate for the reaction, S-adenosyl-L-methionine, was varied in the presence of variable concentrations of pargyline, inhibition of HNMT by pargyline was noncompetitive with regard to the methyl donor, with Kii and Kis values of 1.23 and 0.95 mM, respectively. Pargyline 175-184 histamine N-methyltransferase Homo sapiens 167-171 8147263-13 1993 Finally, several amine compounds related structurally to pargyline were also found to be inhibitors of HNMT. Pargyline 57-66 histamine N-methyltransferase Homo sapiens 103-107 7931265-2 1994 Kinetic considerations show that the rate of reaction of MAO-A with low concentrations of free pargyline will be very much slower than that of MAO-B. Pargyline 95-104 monoamine oxidase A Homo sapiens 57-62 7931265-3 1994 Failure to use adequate reaction times for the concentration of pargyline added can lead to gross underestimation of the quantity of MAO-A present. Pargyline 64-73 monoamine oxidase A Homo sapiens 133-138 8377936-3 1993 Administration of pargyline resulted in the appearance of Fos-positive nuclei distributed along a gradient around the dialysis probe. Pargyline 18-27 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 58-61 8377936-6 1993 In rats not implanted with dialysis probes pargyline administration resulted in only rare Fos-positive nuclei in the dorsal caudate. Pargyline 43-52 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 90-93 7682724-8 1993 The monoamine oxidase (MAO) inhibitors pargyline, i.p., and deprenyl, i.p., as well as the DA agonist apomorphine, i.p., decreased the catechol signal. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 4-21 7682724-8 1993 The monoamine oxidase (MAO) inhibitors pargyline, i.p., and deprenyl, i.p., as well as the DA agonist apomorphine, i.p., decreased the catechol signal. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 23-26 8482527-6 1993 Effects on basal outflow were not observed, when monoamine oxidase (MAO) was inhibited by pargyline. Pargyline 90-99 monoamine oxidase A Rattus norvegicus 49-66 8462004-5 1993 In this study, rats treated with an MAO inhibitor (pargyline) or a nitric oxide synthase inhibitor (LNNA) were protected against O2-induced convulsions. Pargyline 51-60 monoamine oxidase A Rattus norvegicus 36-39 8385528-0 1993 Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Pargyline 71-80 monoamine oxidase A Rattus norvegicus 27-44 8482527-6 1993 Effects on basal outflow were not observed, when monoamine oxidase (MAO) was inhibited by pargyline. Pargyline 90-99 monoamine oxidase A Rattus norvegicus 68-71 1431909-2 1992 Irreversible MAO B inhibitors [(-)-deprenyl, pargyline, and MDL 72,974A] stimulated AADC gene expression, whereas a selective irreversible MAO A inhibitor (clorgyline) and a reversible MAO B inhibitor (Ro 19-6327) had no effect. Pargyline 45-54 monoamine oxidase B Rattus norvegicus 13-18 8469402-5 1993 Such a neurotoxic effect was largely prevented by the monoamine oxidase B inhibitors pargyline and deprenyl, and the dopamine uptake inhibitors mazindol and benztropine. Pargyline 85-94 monoamine oxidase B Mus musculus 54-73 1431909-2 1992 Irreversible MAO B inhibitors [(-)-deprenyl, pargyline, and MDL 72,974A] stimulated AADC gene expression, whereas a selective irreversible MAO A inhibitor (clorgyline) and a reversible MAO B inhibitor (Ro 19-6327) had no effect. Pargyline 45-54 dopa decarboxylase Rattus norvegicus 84-88 1478263-5 1992 produced dose-dependent and significant inhibitory effects on head twitches induced by 5-hydroxytryptophan (5-HTP) plus pargyline, which is a 5-HT2 receptor-dependent behavior in mice. Pargyline 120-129 hypothermia due to alcohol sensitivity 2 Mus musculus 144-147 1478263-6 1992 These results suggest that LS-121 inhibits 5-HTP plus pargyline-induced head twitches by blocking 5-HT2 receptors. Pargyline 54-63 hypothermia due to alcohol sensitivity 2 Mus musculus 100-103 1358631-12 1992 The monoamine oxidase (MAO) inhibitor, pargyline (10-100 microM), did not significantly affect 5-HT-induced contraction. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 23-26 1511517-2 1992 In this study, pregnant animals were pre-treated with the MAO inhibitor pargyline (200 mg/kg i.p. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 58-61 1413647-7 1992 Possible biological significance of alterations in the amine oxidases ratio in the growing placenta is discussed considering the known property of the MAO-B inhibitor pargyline to cause abortion within early periods of pregnancy. Pargyline 167-176 monoamine oxidase B Homo sapiens 151-156 1388247-4 1992 In whole mouse brains, the histamine turnover was significantly inhibited by the 5-HT1A agonists, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (greater than 0.5 mg/kg) and buspirone (greater than 2 mg/kg) injected s.c. 10 min before pargyline treatment. Pargyline 239-248 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 81-87 1567380-2 1992 The nematode enzyme was clearly distinguishable from monoamine and diamine oxidases as well as from the mammalian polyamine oxidase, as shown by the use of the specific inhibitors pargyline, aminoguanidine and MDL 72527 respectively. Pargyline 180-189 polyamine oxidase Homo sapiens 114-131 1631902-3 1992 Inhibitor studies using the specific SSAO inhibitor semicarbazide and the monoamine oxidase inhibitor pargyline indicate that SSAO is responsible for metabolism of methylamine to formaldehyde. Pargyline 102-111 amine oxidase, copper containing 3 Rattus norvegicus 126-130 1567465-3 1992 Metabolism of 100 microM aminoacetone was completely inhibited by 1 mM propargylamine and MDL 72145, drugs which are capable of inhibiting the membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity found in vascular smooth muscle cells, whereas 1 mM pargyline and deprenyl which are inhibitors of monoamine oxidase, were without inhibitory effect. Pargyline 264-273 amine oxidase copper containing 2 Homo sapiens 158-195 1567465-3 1992 Metabolism of 100 microM aminoacetone was completely inhibited by 1 mM propargylamine and MDL 72145, drugs which are capable of inhibiting the membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity found in vascular smooth muscle cells, whereas 1 mM pargyline and deprenyl which are inhibitors of monoamine oxidase, were without inhibitory effect. Pargyline 264-273 amine oxidase copper containing 2 Homo sapiens 197-201 1628144-9 1992 The inhibition of brain COMT activity was estimated by decreases of hypothalamic and striatal homovanillic acid (HVA) and 3-methoxytyramine (3-MT; after pargyline) levels. Pargyline 153-162 catechol-O-methyltransferase Rattus norvegicus 24-28 1309756-7 1992 Furthermore, reaction of either clorgyline or another mechanism-based inhibitor, pargyline, with the membrane-bound enzyme during ATP depletion inhibited the insertion of monoamine oxidase A when ATP was restored. Pargyline 81-90 monoamine oxidase A Rattus norvegicus 171-190 1665214-2 1991 Pretreatment with the monoamine oxidase B inhibitor pargyline largely eliminated the perikaryal radiolabeling in the substantia nigra, dorsal raphe and cerebellum, leaving that in the other regions intact. Pargyline 52-61 monoamine oxidase B Rattus norvegicus 22-41 1686901-0 1991 Synthesis, biological evaluation and quantitative structure activity relationship analysis of nuclear-substituted pargylines as competitive inhibitors of MAO-A and MAO-B. Pargyline 114-124 monoamine oxidase A Homo sapiens 154-159 1686901-0 1991 Synthesis, biological evaluation and quantitative structure activity relationship analysis of nuclear-substituted pargylines as competitive inhibitors of MAO-A and MAO-B. Pargyline 114-124 monoamine oxidase B Homo sapiens 164-169 1686901-1 1991 A series of nuclear substituted derivatives of pargyline has been prepared and tested (under controlled conditions designed to measure the competitive component of the inhibition) as competitive inhibitors of MAO-A and -B. Pargyline 47-56 monoamine oxidase A Homo sapiens 209-221 2016753-5 1991 Inhibition of MAO activity with pargyline in vivo did not affect the pattern of IDPN- or DMAPN-induced toxicity. Pargyline 32-41 monoamine oxidase A Rattus norvegicus 14-17 1766471-10 1991 In pargyline-treated rats, COMT inhibitors did not alter dopamine, DOPAC or HVA levels but all of them decreased significantly 3-MT levels, particularly Ro 41-0960. Pargyline 3-12 catechol-O-methyltransferase Rattus norvegicus 27-31 1766471-13 1991 COMT inhibitors suppressed 3-OMD formation also in clorgyline and pargyline (+ levodopa/carbidopa) treated rats. Pargyline 66-75 catechol-O-methyltransferase Rattus norvegicus 0-4 1757301-3 1991 We investigated the relationship between regional generation of hydrogen peroxide (H2O2) in the brain in the presence of an irreversible inhibitor of catalase, aminotriazole (ATZ), and protection from CNS O2 toxicity by a monoamine oxidase (MAO) inhibitor, pargyline. Pargyline 257-266 catalase Rattus norvegicus 150-158 1757301-7 1991 Pargyline, administered 30 min before HBO, inhibited MAO by greater than 90%, prevented ATZ inhibition of catalase activity during HBO, and reversed the augmentation of CNS O2 toxicity by ATZ. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 53-56 1757301-7 1991 Pargyline, administered 30 min before HBO, inhibited MAO by greater than 90%, prevented ATZ inhibition of catalase activity during HBO, and reversed the augmentation of CNS O2 toxicity by ATZ. Pargyline 0-9 catalase Rattus norvegicus 106-114 1933335-6 1991 However, both pargyline and deprenyl also inhibited cytochrome P-450 mediated aminopyrine N-demethylase activity in brain slices. Pargyline 14-23 cytochrome P450, family 21, subfamily a, polypeptide 1 Mus musculus 52-68 2039542-6 1991 After incubation with radioactively-labeled pargyline polyacrylamide-gel electrophoresis in the presence of sodium dodecyl sulphage (SDS-PAGE) showed the radioactivity to be associated with a peptide of approximate Mr 50,000, corresponding to the subunit of MAO. Pargyline 44-53 monoamine oxidase A Rattus norvegicus 258-261 1682049-6 1991 Pargyline produced an increase in TH-like immunoreactivity and the disappearance of MAO activity. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 84-87 1700071-5 1990 5-HT oxidation to 5-HIAA is carried out principally by MAO-A, because clorgyline was more effective at inhibiting the production of 5-HIAA than was pargyline. Pargyline 148-157 monoamine oxidase A Rattus norvegicus 55-60 1705768-6 1990 Pargyline reversed the latter effects of AII. Pargyline 0-9 angiotensinogen Rattus norvegicus 41-44 1700071-6 1990 Radioenzymatic determinations of MAO activity in cell homogenates supported these findings, because under these conditions clorgyline was 1,000-fold more effective than pargyline at inhibiting MAO activity toward 14C-labelled 5-HT. Pargyline 169-178 monoamine oxidase A Rattus norvegicus 193-196 2153070-1 1990 Inhibition of monoamine oxidase B (MAO B) by selective inhibitors pargyline and L-deprenyl increases dopamine (DA) and norepinephrine (NE) concentrations in nucleus accumbens (NACB) and is associated with reduction in cold water restraint-induced gastric mucosal injury, inhibition of basal gastric acid output, and regional gastric mucosal blood flow. Pargyline 66-75 monoamine oxidase B Rattus norvegicus 14-33 2384758-10 1990 There was also a parallel between the capacity of clorgyline and pargyline, irreversible MAO inhibitors, to decrease the formation of the pyridinium species and their capacity to protect against the toxic actions of the tetrahydropyridines. Pargyline 65-74 monoamine oxidase A Rattus norvegicus 89-92 1971009-3 1990 This CA.OC was suppressed after inhibition of monoamine oxidase by pargyline or after inhibition of tyrosine hydroxylase by alpha-methyl-p-tyrosine and was markedly increased after blockade of dopamine-beta-hydroxylase by FLA 63. Pargyline 67-76 dopamine beta-hydroxylase Rattus norvegicus 193-218 1695859-6 1990 Senktide-induced wet dog shakes were enhanced by the 5-HT reuptake inhibitors citalopram and fluoxetine, suppressed by the monoamine oxidase (MAO)-B inhibitor pargyline, but unaffected by the MAO-A inhibitor clorgyline. Pargyline 159-168 monoamine oxidase B Canis lupus familiaris 123-148 2117053-13 1990 The nonselective MAO inhibitor pargyline caused similar but more pronounced alterations in these parameters. Pargyline 31-40 monoamine oxidase A Rattus norvegicus 17-20 2298362-8 1990 MAO-B inhibitors (pargyline [55%], deprenyl [43%]) but not MAO-A inhibitors (clorgyline [91%]) significantly decreased the frequency of duodenal ulcers suggesting that, like MPTP-induced parkinsonism, formation of a toxic metabolite, probably 1-methyl-4-phenyl-pyridinium is involved. Pargyline 18-27 monoamine oxidase B Rattus norvegicus 0-5 2153070-1 1990 Inhibition of monoamine oxidase B (MAO B) by selective inhibitors pargyline and L-deprenyl increases dopamine (DA) and norepinephrine (NE) concentrations in nucleus accumbens (NACB) and is associated with reduction in cold water restraint-induced gastric mucosal injury, inhibition of basal gastric acid output, and regional gastric mucosal blood flow. Pargyline 66-75 monoamine oxidase B Rattus norvegicus 35-40 2309157-6 1990 Pretreatment with the MAO-B inhibitor pargyline afforded a selective and complete protection of striatal dopamine levels without significantly affecting MPTP-induced striatal serotonin depletions. Pargyline 38-47 monoamine oxidase B Rattus norvegicus 22-27 2111588-7 1990 Selective accumulation of [125I]MHTP-derived radioactivity within these structures was blocked by pretreatment with pargyline, suggesting that monoamine oxidase B is involved in the bioactivation of radioiodinated MHTP. Pargyline 116-125 monoamine oxidase B Homo sapiens 143-162 34908406-0 2021 Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. Pargyline 16-25 lysine demethylase 1A Homo sapiens 29-33 34908406-0 2021 Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. Pargyline 16-25 histone deacetylase 9 Homo sapiens 52-56 34908406-1 2021 Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer agents. Pargyline 23-32 lysine demethylase 1A Homo sapiens 36-40 34908406-1 2021 Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer agents. Pargyline 23-32 histone deacetylase 9 Homo sapiens 89-93 2770890-2 1989 The slices were preincubated with 3H-5-HT 0.1 mumol/l in the presence of the irreversible MAO inhibitor pargyline 50 mumol/l and then continuously superfused. Pargyline 104-113 monoamine oxidase A Rattus norvegicus 90-93 34884655-0 2021 Tryptophan Hydroxylase 2 Deficiency Modifies the Effects of Fluoxetine and Pargyline on the Behavior, 5-HT- and BDNF-Systems in the Brain of Zebrafish (Danio rerio). Pargyline 75-84 tryptophan hydroxylase 1b Danio rerio 0-24 34641548-2 2021 Compounds NEA3 and NEA1 exhibited a more potent MAO-B inhibition (IC50 value = 0.0092 and 0.016 microM, respectively) than the standards (IC50 value = 0.11 and 0.14 microM, respectively, for lazabemide and pargyline). Pargyline 206-215 monoamine oxidase B Homo sapiens 48-53 2571685-7 1989 The addition of pargyline to the coculture abolishes the neurotoxicity consistent with a role of MAO B in bioactivation of MPTP. Pargyline 16-25 monoamine oxidase B Mus musculus 97-102 2501477-5 1989 Administration of clorgyline (1 mg/kg) or pargyline (5 mg/kg) almost inhibited completely MAO-A in the mouse forebrain, and pargyline also almost inhibited completely MAO-B. Pargyline 42-51 monoamine oxidase A Mus musculus 90-95 2501477-5 1989 Administration of clorgyline (1 mg/kg) or pargyline (5 mg/kg) almost inhibited completely MAO-A in the mouse forebrain, and pargyline also almost inhibited completely MAO-B. Pargyline 124-133 monoamine oxidase B Mus musculus 167-172 34884655-0 2021 Tryptophan Hydroxylase 2 Deficiency Modifies the Effects of Fluoxetine and Pargyline on the Behavior, 5-HT- and BDNF-Systems in the Brain of Zebrafish (Danio rerio). Pargyline 75-84 brain-derived neurotrophic factor Danio rerio 112-116 34884655-9 2021 Fluoxetine decreased mRNA levels of Tph2 and Htr2aa genes, while pargyline decreased mRNA levels of Slc6a4b and Htr1aa genes. Pargyline 65-74 solute carrier family 6 member 4b Danio rerio 100-107 34884655-9 2021 Fluoxetine decreased mRNA levels of Tph2 and Htr2aa genes, while pargyline decreased mRNA levels of Slc6a4b and Htr1aa genes. Pargyline 65-74 5-hydroxytryptamine (serotonin) receptor 1A a Danio rerio 112-118 34884655-10 2021 Pargyline reduced Creb, Bdnf and Ntrk2a genes mRNA concentration only in the zebrafish treated with pCPA. Pargyline 0-9 brain-derived neurotrophic factor Danio rerio 24-28 34884655-10 2021 Pargyline reduced Creb, Bdnf and Ntrk2a genes mRNA concentration only in the zebrafish treated with pCPA. Pargyline 0-9 neurotrophic tyrosine kinase, receptor, type 2a Danio rerio 33-39 34432783-0 2021 (Decrease in the Activity of Striatal-Enriched Protein-Tyrosine-Phosphatase (STEP) in the Brain of Danio rerio Treated with p-Chlorophenylalanine and Pargyline). Pargyline 150-159 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 77-81 34432783-4 2021 Reduction or elevation of the serotonin level in the brain of mice caused by the administration of p-chlorophenylalanine or pargyline, respectively, results in a decrease in the level of ptpn5 mRNA in the striatum, ptpn5 being the gene encoding STEP. Pargyline 124-133 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 187-192 34432783-4 2021 Reduction or elevation of the serotonin level in the brain of mice caused by the administration of p-chlorophenylalanine or pargyline, respectively, results in a decrease in the level of ptpn5 mRNA in the striatum, ptpn5 being the gene encoding STEP. Pargyline 124-133 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 215-220 34432783-4 2021 Reduction or elevation of the serotonin level in the brain of mice caused by the administration of p-chlorophenylalanine or pargyline, respectively, results in a decrease in the level of ptpn5 mRNA in the striatum, ptpn5 being the gene encoding STEP. Pargyline 124-133 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 245-249 34432783-9 2021 Both p-chlorophenylalanine and pargyline decrease STEP activity in the D. rerio brain, without affecting the level of the ptpn5 mRNA gene. Pargyline 31-40 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 50-54 35105345-10 2022 PYCR1 was inhibited by siRNA or the small molecule inhibitor pargyline. Pargyline 61-70 pyrroline-5-carboxylate reductase 1 Homo sapiens 0-5 35105345-21 2022 Finally, combination therapy of pargyline with bortezomib reduced viability in CD138+ MM cells and reduced tumor burden in the murine 5TGM1 model compared to single agents. Pargyline 32-41 syndecan 1 Mus musculus 79-84 2495009-1 1989 The concentrations of monoamine oxidase-A and -B were determined in homogenates of human cerebral cortex, caudatus and placenta and in human platelet-rich plasma and platelet membranes by determining the specific binding of tritium-labelled pargyline. Pargyline 241-250 monoamine oxidase A Homo sapiens 22-48 2470944-3 1989 The HA turnover, measured either by the accumulation of t-MH after pargyline injection or by the HA depletion after the treatment with alpha-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase, was enhanced by the exposure to tail pinch, like the enhancement produced by the exposure to foot shock. Pargyline 67-76 histidine decarboxylase Mus musculus 188-211 3263863-9 1988 However, the combined MAO-B/MAO-A inhibitor pargyline had no effect if added after 2 hr of incubation. Pargyline 44-53 monoamine oxidase A Mus musculus 28-33 2532443-4 1989 By using both a monoamine oxidase (MAO) inhibitor (pargyline) and a serotonin precursor, 5-hydroxytryptophan rather than L-tryptophan, with or without an inhibitor of serotonin synthesis, p-chlorophenylalanine, we have demonstrated that many LC neurons have the capacity to accumulate serotonin and not other indoleamines. Pargyline 51-60 monoamine oxidase A Rattus norvegicus 35-38 2538767-1 1989 The stable analogues of adenosine, N-ethylcarboxamidoadenosine (NECA), R-phenylisopropyladenosine (R-PIA) and cyclohexyladenosine (CHA), dose-dependently decreased levels of 3-methoxytyramine (3-MT) in the striatum and antagonized pargyline-dependent accumulation of 3-methoxytyramine. Pargyline 231-240 ribose 5-phosphate isomerase A Rattus norvegicus 71-104 3265770-6 1988 Additionally, pargyline pretreatment prevented both the rise in GFAP and the decrease in dopamine in striatum. Pargyline 14-23 glial fibrillary acidic protein Mus musculus 64-68 3139835-2 1988 The MAO inhibitors pargyline, clorgyline, and deprenyl all yielded biphasic competition curves versus [3H]tryptamine. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 4-7 2842890-4 1988 Clorgyline and pargyline were used as inhibitors of monoamine oxidase (MAO) A and B, respectively. Pargyline 15-24 monoamine oxidase A Rattus norvegicus 52-83 2455784-3 1988 When the MAO inhibitor pargyline was injected and the animals killed at different times, there was an exponential decrease in the concentration of 5-hydroxyindole acetic acid (5-HIAA) with time, whereas the increase in 5-hydroxytryptamine was linear only during the first 30 min, thereafter reaching a plateau. Pargyline 23-32 monoamine oxidase A Rattus norvegicus 9-12 2907098-3 1988 When MAO activity was inhibited by pargyline (10 mumol/l), p-tyramine and p-octopamine had mixed excitatory-inhibitory effects on the twitches, while noradrenaline had mostly excitatory effects along the whole range of concentrations assayed (0.158-15.8 mumol/l). Pargyline 35-44 monoamine oxidase A Rattus norvegicus 5-8 2467272-2 1988 Administration of the serotonin precursor, 5-hydroxytryptophan (5-HTP; 250 mg/kg ip) or pargyline (5 mg/kg ip) with 5-HTP (100 mg/kg ip) significantly increased serum prolactin concentration. Pargyline 88-97 prolactin Rattus norvegicus 167-176 2963592-7 1988 Moreover, the monoamine oxidase B inhibitor, pargyline, prevented the rise in cytosolic free Ca2+ concentration and partially protected the plasma membrane Ca2+-ATPase from inhibition by MPTP. Pargyline 45-54 monoamine oxidase B Homo sapiens 14-33 2963592-7 1988 Moreover, the monoamine oxidase B inhibitor, pargyline, prevented the rise in cytosolic free Ca2+ concentration and partially protected the plasma membrane Ca2+-ATPase from inhibition by MPTP. Pargyline 45-54 ATPase plasma membrane Ca2+ transporting 2 Homo sapiens 140-167 3121972-1 1988 Pargyline, an inhibitor of monoamine oxidase type B (MAO-B), did not prevent the depletion of heart norepinephrine 24 hr after a single dose of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in mice. Pargyline 0-9 monoamine oxidase B Mus musculus 27-51 3121972-3 1988 These results with pargyline are the same as results obtained earlier with deprenyl, another selective inhibitor of MAO-B. Pargyline 19-28 monoamine oxidase B Mus musculus 116-121 3121972-4 1988 The doses of pargyline and of deprenyl that were used resulted in almost complete inhibition of MAO-B activity (phenylethylamine as substrate) in brain, heart and liver of mice. Pargyline 13-22 monoamine oxidase B Mus musculus 96-101 3121972-5 1988 Deprenyl did not inhibit MAO-A activity (serotonin as substrate) in brain, but pargyline caused some inhibition of MAO-A in brain. Pargyline 79-88 monoamine oxidase A Mus musculus 115-120 3121972-7 1988 Both pargyline and deprenyl caused some inhibition of serotonin deamination in heart and liver, suggesting that the oxidation may have been due partly to MAO-B. Pargyline 5-14 monoamine oxidase B Mus musculus 154-159 3342079-4 1988 Pargyline, another inhibitor of AlDH, maintained normal blood acetone levels in the presence of reduced acetoacetate levels. Pargyline 0-9 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 32-36 3213579-2 1988 Pargyline (75 mg/kg, s.c.), a monoamine oxidase (MAO) inhibitor, was administered 30 min prior to decapitation. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 30-47 3213579-2 1988 Pargyline (75 mg/kg, s.c.), a monoamine oxidase (MAO) inhibitor, was administered 30 min prior to decapitation. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 49-52 3148140-4 1988 Pargyline did not increase the reinforcement rate at low doses that selectively inhibit MAO-B, but did increase the reinforcement rate at doses that inhibit MAO-A by more than 90%. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 157-162 2851858-11 1988 In synaptic plasma membranes prepared from rats repeatedly treated with pargyline (at doses which block MAO tipo A and B) but not with minaprine, the number of 5HT1C and 5HT2 receptors was reduced. Pargyline 72-81 5-hydroxytryptamine receptor 2C Rattus norvegicus 160-165 3664088-8 1987 In vitro treatment with the monoamine oxidase (MAO) inhibitors, iproniazid or pargyline, did not potentiate responses to either noradrenaline or isoprenaline. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 28-45 3632702-7 1987 MAO-B was titrated with unlabelled pargyline, deprenyl and [3H]-pargyline; the corresponding Kcat values, turnover number and the active concentrations were then determined. Pargyline 35-44 monoamine oxidase B Sus scrofa 0-5 3632702-8 1987 The molecular weight of MAO-B present in both cellular fractions was calculated by SDS-electrophoresis and fluorography, after reaction with [3H]-pargyline. Pargyline 146-155 monoamine oxidase B Sus scrofa 24-29 2886556-4 1987 Molecular forms of MAO were examined by using specific MAO inhibitors, and by polyacrylamide gel electrophoresis after [3H]pargyline binding. Pargyline 123-132 monoamine oxidase A Rattus norvegicus 19-22 3683592-3 1987 The extraneuronal COMT activity was determined under conditions of inhibition of both neuronal uptake and MAO (pretreatment with pargyline). Pargyline 129-138 catechol-O-methyltransferase Rattus norvegicus 18-22 3683592-3 1987 The extraneuronal COMT activity was determined under conditions of inhibition of both neuronal uptake and MAO (pretreatment with pargyline). Pargyline 129-138 monoamine oxidase A Rattus norvegicus 106-109 3664088-8 1987 In vitro treatment with the monoamine oxidase (MAO) inhibitors, iproniazid or pargyline, did not potentiate responses to either noradrenaline or isoprenaline. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 47-50 2885213-0 1987 Somatostatin immunoneutralization overcomes the inhibitory effects of quipazine and pargyline on growth hormone secretion in domestic fowl. Pargyline 84-93 growth hormone Gallus gallus 97-111 2885213-1 1987 The inhibitory effects of pargyline and quipazine on chicken growth hormone secretion were overcome by passive immunoneutralization of endogenous somatostatin (SRIF)-14 or SRIF-28(1-14)-like immunoreactivity. Pargyline 26-35 growth hormone Gallus gallus 61-75 3102694-4 1987 Monoamine oxidase B inhibitors (e.g., pargyline, MDL 72145) relieve the inhibition caused by MPTP but not MPP+. Pargyline 38-47 monoamine oxidase B Rattus norvegicus 0-19 2885213-1 1987 The inhibitory effects of pargyline and quipazine on chicken growth hormone secretion were overcome by passive immunoneutralization of endogenous somatostatin (SRIF)-14 or SRIF-28(1-14)-like immunoreactivity. Pargyline 26-35 somatostatin 1 Gallus gallus 160-164 2885213-1 1987 The inhibitory effects of pargyline and quipazine on chicken growth hormone secretion were overcome by passive immunoneutralization of endogenous somatostatin (SRIF)-14 or SRIF-28(1-14)-like immunoreactivity. Pargyline 26-35 somatostatin 1 Gallus gallus 172-176 3566791-8 1987 With the same digestion and separation procedures, only one major radioactive peak was observed for the [3H]pargyline-labeled MAO-B, and its elution volume was different from that of [3H]FNPA-labeled peptides. Pargyline 108-117 monoamine oxidase B Homo sapiens 126-131 3103805-0 1987 N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl. Pargyline 46-55 monoamine oxidase B Rattus norvegicus 82-106 2442302-2 1987 The disappearance of 5-HTOL following monoamine oxidase (MAO) inhibition induced by pargyline was more rapid (t1/2 10-15 min) than that of 5-HIAA (t1/2 30-40 min) in all regions investigated, indicating a rapid turnover of 5-HTOL. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 38-55 2442302-2 1987 The disappearance of 5-HTOL following monoamine oxidase (MAO) inhibition induced by pargyline was more rapid (t1/2 10-15 min) than that of 5-HIAA (t1/2 30-40 min) in all regions investigated, indicating a rapid turnover of 5-HTOL. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 57-60 20501066-6 1987 They could be protected by the presence of the substrate (phenylethylamine) or inhibitors (pargyline and trans-phenylcyclopropylamine) of MAO-B during photolysis. Pargyline 91-100 monoamine oxidase B Homo sapiens 138-143 3780861-7 1986 pargyline produced equivalent inhibition of rat brain MAO and decreased the binding of [3H]clonidine and [3H]RX 781094 to the alpha 2-adrenoceptor and of [3H]dihydroalprenolol to the beta-adrenoceptor without changing binding of [3H]prazosin to the alpha 1-adrenoceptor. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 54-57 3091132-5 1986 Repeated but not single treatment with the nonselective and irreversible MAO inhibitors nialamide and pargyline reduced markedly the ejaculatory response but only slightly the 5-HT behavioural responses. Pargyline 102-111 monoamine oxidase A Rattus norvegicus 73-76 3730457-1 1986 Behavioral depression produced by exposing animals to a stressor that they cannot control (uncontrollable shock) was reversed by infusion of the monoamine oxidase (MAO) inhibitor pargyline into the locus coeruleus (LC) region of the brain stem. Pargyline 179-188 monoamine oxidase A Rattus norvegicus 145-162 3730457-1 1986 Behavioral depression produced by exposing animals to a stressor that they cannot control (uncontrollable shock) was reversed by infusion of the monoamine oxidase (MAO) inhibitor pargyline into the locus coeruleus (LC) region of the brain stem. Pargyline 179-188 monoamine oxidase A Rattus norvegicus 164-167 3487620-3 1986 This effect was abolished by pretreatment with pargyline, a MAOB inhibitor, suggesting that oxidation of MPTP to the pyridinium moiety, MPP+, is a necessary step for toxicity when mazindol binding is used as an end point. Pargyline 47-56 monoamine oxidase B Mus musculus 60-64 3527152-3 1986 The antibody indirectly precipitates [3H]pargyline-labelled human MAO B both from liver and platelet extracts but fails to precipitate MAO A from liver extracts. Pargyline 41-50 monoamine oxidase B Homo sapiens 66-71 2885213-3 1987 These results suggest that peptides with SRIF-14 or SRIF-28(1-14)-like immunoreactivity tonically inhibit GH secretion and are at least partially responsible for the inhibitory effects of pargyline and quipazine on GH release in immature domestic fowl. Pargyline 188-197 somatostatin 1 Gallus gallus 41-45 3668521-1 1987 The treatment of Sprague-Dawley rats with monoamine oxidase (MAO) inhibitors (pargyline, tranylcypromine) profoundly affects dopamine (DA) and norepinephrine (NE) metabolism in the brain. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 42-59 3668521-1 1987 The treatment of Sprague-Dawley rats with monoamine oxidase (MAO) inhibitors (pargyline, tranylcypromine) profoundly affects dopamine (DA) and norepinephrine (NE) metabolism in the brain. Pargyline 78-87 monoamine oxidase A Rattus norvegicus 61-64 3574494-2 1987 The animals had been treated with the MAO inhibitor pargyline (40 mg/kg) 30 min before i.c.v. Pargyline 52-61 monoamine oxidase A Rattus norvegicus 38-41 3790166-1 1986 The concentrations of monoamine oxidase-A and -B have been determined in mitochondria, mitochondrial outer membranes and microsomes from Sprague-Dawley and Wistar rats by determining the binding of tritium-labelled pargyline. Pargyline 215-224 monoamine oxidase A Rattus norvegicus 22-48 3762740-6 1986 Determinations of the activity of MAO in homogenates of vasa deferentia showed that preincubation with 10 and 20 nmol/l pargyline inhibited the enzyme by 80 to 95%. Pargyline 120-129 monoamine oxidase A Rattus norvegicus 34-37 3707613-0 1986 Role of propiolaldehyde and other metabolites in the pargyline inhibition of rat liver aldehyde dehydrogenase. Pargyline 53-62 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 87-109 3707613-10 1986 Other putative metabolites of pargyline, namely benzylamine and propargylamine, inhibited AlDH in vivo, albeit to a lesser degree than pargyline, but neither of these amines inhibited AlDH directly. Pargyline 30-39 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 90-94 3707613-12 1986 From these studies, we conclude that propiolaldehyde was the primary metabolite responsible for the pargyline inhibition of AlDH in vivo; however, certain amine metabolites may have contributed to a lesser degree by conversion to yet unknown inhibitory forms. Pargyline 100-109 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 124-128 3566791-9 1987 These results suggest that, upon photolysis, FNPA may incorporate into a region in the active site of MAO-B which may be different from the pargyline binding site--the FAD prosthetic group of the enzyme. Pargyline 140-149 monoamine oxidase B Homo sapiens 102-107 3945167-1 1986 In mice treated 24 hrs earlier with pargyline (20 mg/kg i.p), both type A and type B monoamine oxidase (MAO-A and MAO-B) were partially inactivated in brain, heart and liver. Pargyline 36-45 monoamine oxidase A Mus musculus 104-109 3945167-1 1986 In mice treated 24 hrs earlier with pargyline (20 mg/kg i.p), both type A and type B monoamine oxidase (MAO-A and MAO-B) were partially inactivated in brain, heart and liver. Pargyline 36-45 monoamine oxidase B Mus musculus 114-119 3945167-7 1986 Antagonism of the pargyline-induced inactivation is interpreted as being due to the transient selective inhibition of MAO-A by harmaline and of MAO-B by MD 240928, preventing the mechanism-based inactivation of those enzymes by pargyline. Pargyline 18-27 monoamine oxidase A Mus musculus 118-123 3945167-7 1986 Antagonism of the pargyline-induced inactivation is interpreted as being due to the transient selective inhibition of MAO-A by harmaline and of MAO-B by MD 240928, preventing the mechanism-based inactivation of those enzymes by pargyline. Pargyline 18-27 monoamine oxidase B Mus musculus 144-149 3945167-7 1986 Antagonism of the pargyline-induced inactivation is interpreted as being due to the transient selective inhibition of MAO-A by harmaline and of MAO-B by MD 240928, preventing the mechanism-based inactivation of those enzymes by pargyline. Pargyline 228-237 monoamine oxidase A Mus musculus 118-123 3697783-3 1986 Inhibition of DA inactivation processes by local application of benztropine (a DA reuptake inhibitor, 10(-6) M) or by IV administration of pargyline (a MAO inhibitor, 100 mg/kg) enhanced the detectable outflow of 3H-DA from the striatum in both halothane anesthetized and awake rats. Pargyline 139-148 monoamine oxidase A Rattus norvegicus 152-155 3010139-1 1986 The adrenergic nerve endings of vasa deferentia of either untreated or reserpine (R) and/or pargyline (P) pretreated rats were loaded with 3H-noradrenaline; COMT was inhibited by U-0521 (U). Pargyline 92-101 catechol-O-methyltransferase Rattus norvegicus 157-161 3930664-3 1985 However, in rats previously treated with the MAO inhibitors pargyline or tranylcypromine, the same L-DOPA or free DA treatment resulted in significant increases in both 3-MT and DA sulfate in the hypothalamus, brainstem, and striatum. Pargyline 60-69 monoamine oxidase A Rattus norvegicus 45-48 3011983-7 1986 Monoamine oxidase inhibitors such as deprenyl, pargyline and harmaline have affinities to the MPTP receptors which parallel their affinity for the B type of monoamine oxidase (MAO B). Pargyline 47-56 monoamine oxidase B Homo sapiens 176-181 4058679-6 1985 Pargyline was a relatively more potent inhibitor of MAO than chlordimeform, but not more efficacious. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 52-55 3990515-5 1985 In contrast, the inhibitory effect of PEA on the LC neurons was strongly potentiated by pretreatment with the selective monoamine oxidase (MAO) - B inhibitor pargyline (2 mg/kg, i.p., 1 h), but, unexpectedly, also by pretreatment with the MAO-A selective inhibitors clorgyline (2 mg/kg, i.p., 1 h) or FLA 336 (2 mg/kg, i.p., 1 h). Pargyline 158-167 monoamine oxidase B Rattus norvegicus 120-147 3929190-1 1985 Pargyline, an inhibitor of monoamine oxidase (MAO), prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced inhibition of dihydroxyphenylalanine (DOPA) production by tyrosine hydroxylase (TH) system in rat striatal tissue slices. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 27-44 3929190-1 1985 Pargyline, an inhibitor of monoamine oxidase (MAO), prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced inhibition of dihydroxyphenylalanine (DOPA) production by tyrosine hydroxylase (TH) system in rat striatal tissue slices. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 46-49 3929190-1 1985 Pargyline, an inhibitor of monoamine oxidase (MAO), prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced inhibition of dihydroxyphenylalanine (DOPA) production by tyrosine hydroxylase (TH) system in rat striatal tissue slices. Pargyline 0-9 tyrosine hydroxylase Rattus norvegicus 180-200 3929190-1 1985 Pargyline, an inhibitor of monoamine oxidase (MAO), prevented 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced inhibition of dihydroxyphenylalanine (DOPA) production by tyrosine hydroxylase (TH) system in rat striatal tissue slices. Pargyline 0-9 tyrosine hydroxylase Rattus norvegicus 202-204 3990515-5 1985 In contrast, the inhibitory effect of PEA on the LC neurons was strongly potentiated by pretreatment with the selective monoamine oxidase (MAO) - B inhibitor pargyline (2 mg/kg, i.p., 1 h), but, unexpectedly, also by pretreatment with the MAO-A selective inhibitors clorgyline (2 mg/kg, i.p., 1 h) or FLA 336 (2 mg/kg, i.p., 1 h). Pargyline 158-167 monoamine oxidase A Rattus norvegicus 239-244 3839173-8 1985 Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 167-170 3872699-0 1985 Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase. Pargyline 94-103 monoamine oxidase A Rattus norvegicus 115-132 3872699-4 1985 Under the conditions of the assay, [3H]pargyline labeled the type B form of MAO. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 76-79 3871853-4 1985 dose antagonized the irreversible inactivation of MAO-A in rat brain by pargyline, indicating that it inhibited MAO-A in vivo. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 112-117 3871853-4 1985 dose antagonized the irreversible inactivation of MAO-A in rat brain by pargyline, indicating that it inhibited MAO-A in vivo. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 50-55 3871244-5 1985 MPTP appeared to inhibit MAO-A in rat brain in vivo as determined by its antagonism of the inactivation of MAO-A by pargyline and by its antagonism of the increase in dopamine metabolites resulting from the administration of Ro 4-1284, a dopamine releaser. Pargyline 116-125 monoamine oxidase A Rattus norvegicus 25-30 3871244-5 1985 MPTP appeared to inhibit MAO-A in rat brain in vivo as determined by its antagonism of the inactivation of MAO-A by pargyline and by its antagonism of the increase in dopamine metabolites resulting from the administration of Ro 4-1284, a dopamine releaser. Pargyline 116-125 monoamine oxidase A Rattus norvegicus 107-112 6092815-7 1984 These findings were reproduced by subacute administration of pargyline, a MAO inhibitor. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 74-77 6332989-6 1984 We now report that pargyline, nialamide and tranylcypromine, which inhibit both MAO-A and MAO-B, when administered to mice before MPTP, protect against MPTP-induced dopaminergic neurotoxicity. Pargyline 19-28 monoamine oxidase A Mus musculus 80-85 6332989-6 1984 We now report that pargyline, nialamide and tranylcypromine, which inhibit both MAO-A and MAO-B, when administered to mice before MPTP, protect against MPTP-induced dopaminergic neurotoxicity. Pargyline 19-28 monoamine oxidase B Mus musculus 90-95 2410561-2 1985 Pargyline, NSD 1015 and alpha-propyldopacetamide all caused an exponential decline of 5-HIAA in both CSF and striatum. Pargyline 0-9 colony stimulating factor 2 Rattus norvegicus 101-104 3991364-2 1985 Although hypermotility induced by methamphetamine was not potentiated by central administration of VIP, L-DOPA-induced hypermotility in pargyline-pretreated rats was markedly enhanced by VIP and this hypermotility was suppressed by simultaneous administration of cholecystokinin octapeptide (CCK-8) in a dose-related manner. Pargyline 136-145 vasoactive intestinal peptide Rattus norvegicus 187-190 6335034-2 1984 MPTP is oxidized by brain mitochondrial preparations in a process which is blocked by deprenyl and pargyline, implying catalysis by monoamine oxidase B. Pargyline 99-108 monoamine oxidase B Homo sapiens 132-151 6150877-8 1984 Pargyline (25 mg/kg) treatment to inhibit serotonin catabolism elevated PRL levels in pituitary and medium during subsequent incubation. Pargyline 0-9 prolactin Oncorhynchus mykiss 72-75 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 41-58 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 60-63 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 213-218 6332989-5 1984 Moreover, in rat brain preparations, the monoamine oxidase (MAO) inhibitor pargyline and the specific MAO-B inhibitor deprenil can prevent the formation of 1-methyl-4-phenyl-pyridine from MPTP, while the specific MAO-A inhibitor clorgyline has no such effect, suggesting that MAO, and specifically MAO-B, is responsible for the oxidative metabolism of MPTP. Pargyline 75-84 monoamine oxidase B Rattus norvegicus 298-303 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 14-31 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 33-36 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 catechol-O-methyltransferase Rattus norvegicus 226-255 6209589-4 1984 The administration of the MAO inhibitor, pargyline, produced dose- and time-related reductions in brain MAO type A and B activities, hypothalamic 5HIAA concentrations and plasma growth hormone levels, but increased the hypothalamic serotonin and plasma prolactin concentrations. Pargyline 41-50 growth hormone 1 Homo sapiens 178-192 6493360-6 1984 On the other hand, after chronic administration of pargyline (10 mg X kg-1), a preferential type B MAO inhibitor, the hypotension and bradycardia caused by clonidine were differently affected. Pargyline 51-60 monoamine oxidase A Rattus norvegicus 99-102 6493360-9 1984 Pargyline, that preferentially inhibits type B MAO, reduces only the bradycardia induced by clonidine. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 47-50 6209589-4 1984 The administration of the MAO inhibitor, pargyline, produced dose- and time-related reductions in brain MAO type A and B activities, hypothalamic 5HIAA concentrations and plasma growth hormone levels, but increased the hypothalamic serotonin and plasma prolactin concentrations. Pargyline 41-50 prolactin Homo sapiens 253-262 6472500-1 1984 Tracheal segments from guinea-pigs pretreated with 6-hydroxydopamine were incubated in 5 or 200 mumol X 1(-1) adrenaline at 37 degrees C. Catechol-O-methyltransferase and monoamine oxidase were inhibited by U-0521 and pargyline, respectively, and the accumulation of adrenaline in trachealis smooth muscle cells was measured by fluorescence microphotometry. Pargyline 218-227 catechol O-methyltransferase Cavia porcellus 138-166 6144276-5 1984 In contrast, treatment of cultures with pargyline caused decreases in the binding of 125I-angiotensin II and increases in catecholamine levels in neuronal cultures. Pargyline 40-49 angiotensinogen Rattus norvegicus 90-104 6539606-3 1984 The same applies to other inhibitors of MAO-A, such as clorgiline and pargyline as well as selegiline (deprenyl) in higher concentrations. Pargyline 70-79 amine oxidase [flavin-containing] A Cavia porcellus 40-45 6717760-2 1984 oxytocin [OXT] have been studied on the steady-state level and pargyline-induced accumulation of serotonin [5-HT] in the hypothalamus, mesencephalon and dorsal hippocampus of rats. Pargyline 63-72 oxytocin/neurophysin I prepropeptide Rattus norvegicus 0-8 6717760-2 1984 oxytocin [OXT] have been studied on the steady-state level and pargyline-induced accumulation of serotonin [5-HT] in the hypothalamus, mesencephalon and dorsal hippocampus of rats. Pargyline 63-72 oxytocin/neurophysin I prepropeptide Rattus norvegicus 10-13 6717760-4 1984 The pargyline-induced accumulation, on the other hand, was inhibited by central OXT treatment. Pargyline 4-13 oxytocin/neurophysin I prepropeptide Rattus norvegicus 80-83 6421606-11 1984 stimulated the accumulation of 3-methoxytyramine and normetanephrine following monoamine oxidase (MAO) inhibition with pargyline. Pargyline 119-128 monoamine oxidase A Rattus norvegicus 79-96 6421606-11 1984 stimulated the accumulation of 3-methoxytyramine and normetanephrine following monoamine oxidase (MAO) inhibition with pargyline. Pargyline 119-128 monoamine oxidase A Rattus norvegicus 98-101 6542783-4 1984 In contrast to amitriptyline and pargyline pirlindole inhibited the MAO with tryptamine as a substrate in the brain 100 times (2.49 X 10(-7) mol/l) and in the heart nearly 1000 times (3.42 X 10(-8) mol/l) more than with phenylethylamine as a substrate (5.21 and 5.99 X 10(-5) mol/l, respectively). Pargyline 33-42 monoamine oxidase A Rattus norvegicus 68-71 6542783-5 1984 These results show that amitriptyline and pargyline are relatively selective inhibitors of MAO B, whereas pirlindole blocks the A-form of MAO much stronger than MAO B. Pargyline 42-51 monoamine oxidase B Rattus norvegicus 91-96 6542783-5 1984 These results show that amitriptyline and pargyline are relatively selective inhibitors of MAO B, whereas pirlindole blocks the A-form of MAO much stronger than MAO B. Pargyline 42-51 monoamine oxidase A Rattus norvegicus 91-94 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 catechol-O-methyltransferase Rattus norvegicus 257-261 6514013-2 1984 Inhibition of monoamine oxidase (MAO) (by pretreatment of the animals with pargyline) increased the formation of O-methylated metabolites by nearly that amount by which the formation of deaminated metabolites declined; hence, catechol-O-methyl transferase (COMT) seemed to be able to nearly fully compensate for the loss of MAO activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 324-327 6697175-1 1984 Rapid and complete inhibition of monoamine oxidase by pargyline produced linear increases in the content of the histamine metabolite, tele-methylhistamine (t-MH), in 9 regions of rat brain 2 and 4 h after drug administration. Pargyline 54-63 POU class 3 homeobox 2 Rattus norvegicus 183-196 6420718-3 1984 When rats were given pargyline (75 mg/kg) prior to the administration of reserpine (2.5 mg/kg), the reserpine-induced alterations in serum prolactin and stalk plasma dopamine concentrations were completely prevented. Pargyline 21-30 prolactin Rattus norvegicus 139-148 6527139-6 1984 In contrast, the preferential inhibitors of MAO B, deprenil, pargyline and MD 780236, as well as the nonselective agent tranylcypromine, caused strong (up to about 60-fold) increases. Pargyline 61-70 monoamine oxidase B Rattus norvegicus 44-49 6420718-4 1984 Pargyline treatment alone resulted in a significant elevation of the concentration of dopamine in pituitary stalk plasma and a reduction in the serum concentration of prolactin. Pargyline 0-9 prolactin Rattus norvegicus 167-176 6227192-5 1983 The in vitro responsiveness of the pituitary gland to hypothalamic stimuli eliciting prolactin secretion was increased by in vivo pargyline and combined tryptophan: imipramine treatment but reduced by PCPA administration. Pargyline 130-139 prolactin Gallus gallus 85-94 6227192-6 1983 The in vitro GH response to hypothalamic stimulation was reduced after the in vivo injection of pargyline, clorgyline and tryptophan: imipramine. Pargyline 96-105 growth hormone Gallus gallus 13-15 6419132-6 1983 In the case of pargyline, a less selective MAO-B inhibitor, the preference in favour of phenylethylamine was less pronounced. Pargyline 15-24 monoamine oxidase B Rattus norvegicus 43-48 6622205-3 1983 This makes these compounds more than 10 000 times less potent than the selective MAO-A inhibitor harmaline and more than 10 times less potent than the selective MAO-B inhibitors pargyline and deprenyl. Pargyline 178-187 monoamine oxidase B Rattus norvegicus 161-166 7326580-2 1981 Some animals were also given the monoamine oxidase (MAO) inhibitor pargyline at designated times 10-40 min prior to sacrifice. Pargyline 67-76 monoamine oxidase A Rattus norvegicus 52-55 6191193-4 1983 The concentration of immunologically detectable MAO B protein in the extracts was estimated from immunoprecipitation competition data by reference to a standard curve relating observed inhibition of immunoprecipitation to the concentration of catalytically active platelet MAO added (estimated from [3H]pargyline binding data). Pargyline 303-312 monoamine oxidase B Homo sapiens 48-53 6856953-2 1983 antagonized the inactivation of MAO by pargyline as measured by direct enzyme assays in brain homogenates and by accumulation of hypothalamic catecholamines. Pargyline 39-48 monoamine oxidase A Rattus norvegicus 32-35 6650186-3 1983 Serotonin turnover, measured by serotonin accumulation induced by the MAO inhibitor pargyline, decreased in the mesencephalon. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 70-73 6139243-1 1983 Adult fowl of both sexes injected with the monoamine oxidase inhibitor pargyline showed elevated circulating prolactin concentrations and reduced growth hormone concentrations. Pargyline 71-80 growth hormone 1 Homo sapiens 146-160 6822482-2 1983 The pharmacologic actions of pargyline are discussed with regard to its partial selectivity for MAO-B and presumed action in dopamine systems, and clinicians are alerted to this uncommon drug reaction. Pargyline 29-38 monoamine oxidase B Homo sapiens 96-101 6131854-3 1982 2) When it was measured by the accumulation of 3-methoxytyramine in the neostriatum and limbic forebrain of pargyline (MAO inhibitor)-pretreated rats, lisuride at the low dosage caused the inhibition of not only the spontaneous release of dopamine from the nerve terminal to the synaptic cleft, but also the release induced with methamphetamine. Pargyline 121-130 monoamine oxidase A Rattus norvegicus 132-135 6808207-7 1982 The titration experiment of MAO by pargyline suggests that the decrease of MAO activity, in vitro, is mainly due to the decrease of active MAO molecules in these mitochondrial preparations from livers of rats ingesting 3"-Me-DAB. Pargyline 35-44 monoamine oxidase A Rattus norvegicus 28-31 6808207-7 1982 The titration experiment of MAO by pargyline suggests that the decrease of MAO activity, in vitro, is mainly due to the decrease of active MAO molecules in these mitochondrial preparations from livers of rats ingesting 3"-Me-DAB. Pargyline 35-44 monoamine oxidase A Rattus norvegicus 75-78 6808207-7 1982 The titration experiment of MAO by pargyline suggests that the decrease of MAO activity, in vitro, is mainly due to the decrease of active MAO molecules in these mitochondrial preparations from livers of rats ingesting 3"-Me-DAB. Pargyline 35-44 monoamine oxidase A Rattus norvegicus 75-78 7098495-3 1982 The method clearly showed that clorgyline (a preferential type A inhibitor) preferentially inhibited rat heart MAO; whereas pargyline (a preferential type B inhibitor) preferentially inhibited mouse heart MAO. Pargyline 124-133 monoamine oxidase A Rattus norvegicus 205-208 6287499-1 1982 The hypothesis that pargyline, a monoamine oxidase inhibitor, may interact with pineal beta-adrenergic receptors to increase N-acetyltransferase (NAT) activity and, thereby, melatonin content was tested in intact and superior cervical ganglionectomized (SCGX) rats some of which were also treated with the tryptophan hydroxylase inhibitor para-chlorophenylalanine (PCPA). Pargyline 20-29 N-acetyltransferase 1 Rattus norvegicus 146-149 6287499-2 1982 Pargyline injection increased both NAT activity and melatonin content, an effect nullified by conjunct propranolol injection. Pargyline 0-9 N-acetyltransferase 1 Rattus norvegicus 35-38 6287499-3 1982 While pargyline injection also increased NAT activity in intact, PCPA-treated rats, the effects of this drug were most evident in SCGX, PCPA-treated rats. Pargyline 6-15 N-acetyltransferase 1 Rattus norvegicus 41-44 6287499-5 1982 We suggest that pargyline may be capable of interacting with pineal beta-adrenergic receptors to increase NAT activity in the absence of pineal norepinephrine (NE) and serotonin. Pargyline 16-25 N-acetyltransferase 1 Rattus norvegicus 106-109 6542783-0 1984 [Inhibition of monoamine oxidase A and B in the heart and brain of the rat with amitriptyline, pargyline and pirlindol]. Pargyline 95-104 monoamine oxidase A Rattus norvegicus 15-40 6542783-1 1984 The inhibition of monoamine oxidase (MAO) A and B by amitriptyline, pargyline and pirlindole was measured in heart and brain homogenates of rats with tryptamine and beta-phenylethylamine as substrates. Pargyline 68-77 monoamine oxidase A Rattus norvegicus 18-43 6359210-4 1983 Pargyline inhibits monoamine oxidase, type B, and its therapeutic efficacy is compatible with the hypothesis that decreased phenethylaminergic function, dopaminergic function, or both play a role in the etiology of the disorder. Pargyline 0-9 monoamine oxidase B Homo sapiens 19-44 6847697-1 1983 [3H]Pargyline-labeled polypeptides associated with the A and B types of monoamine oxidase (MAO) activity in two rat cell lines were compared by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Pargyline 4-13 monoamine oxidase A Rattus norvegicus 91-94 6847697-8 1983 Furthermore, when SDS-solubilized, [3H]pargyline-labeled MAO A and B proteins from these cell lines were subjected to limited proteolysis and one-dimensional peptide mapping in SDS gels, different patterns of [3H]pargyline-labeled peptides were obtained. Pargyline 39-48 monoamine oxidase A Homo sapiens 57-62 6401800-10 1983 Indomethacin (2 x 10(-4) M), catalase (50 micrograms/ml), and pargyline (2 x 10(-4) M) eliminated the MAO-dependent mitochondrial synthesis of PG endoperoxides. Pargyline 62-71 monoamine oxidase A Rattus norvegicus 102-105 20487950-6 1983 Treatment with pargyline (75 mg kg(?1)), a monoamine oxidase inhibitor, resulted in an increase in 5-HT content with parallel modifications in CAT activity. Pargyline 15-24 choline O-acetyltransferase Rattus norvegicus 143-146 6856588-2 1983 As a first step, placental MAO content and its sensitivity to inhibition by pargyline were assessed in incubation studies of homogenates as well as during perfusion, taking rat liver as reference. Pargyline 76-85 monoamine oxidase A Rattus norvegicus 27-30 6856588-4 1983 MAO inhibition by pargyline significantly reduced the NA clearance from maternal to fetal circulation. Pargyline 18-27 monoamine oxidase A Rattus norvegicus 0-3 7150951-1 1982 Administration of the MAO-inhibitor pargyline resulted in an increase of dopamine (DA) and an exponential decrease of the metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in various rat brain areas. Pargyline 36-45 monoamine oxidase A Rattus norvegicus 22-25 6817759-0 1982 The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Pargyline 130-139 monoamine oxidase A Rattus norvegicus 42-73 6817759-5 1982 Pargyline shows a Ki value towards monoamine oxidase B that is only 8 times lower than that towards the A-form and in this case the rates of formation of the enzyme-inhibitor adducts are similar. Pargyline 0-9 monoamine oxidase B Rattus norvegicus 35-54 7127078-3 1982 Des-Tyr1-a-endorphin (beta-endorphin2-16; DTaE), on the other hand, inhibits the accumulation of serotonin following MAO-inhibition by pargyline in all 3 brain regions, while, in addition to causing a transient reduction in the serotonin concentration of the raphe area, it decreases the serotonin concentration of the mediobasal hypothalamus. Pargyline 135-144 monoamine oxidase A Rattus norvegicus 117-120 6123960-3 1982 In contrast pargyline, which only partially inhibited MAO-A, caused only a nonsignificant (7%) change in rat cortical beta-receptor binding. Pargyline 12-21 monoamine oxidase A Rattus norvegicus 54-59 6279462-1 1982 Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 21-38 6279462-1 1982 Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 40-43 6279462-1 1982 Inhibition of pineal monoamine oxidase (MAO) activity either by harmine or pargyline in adult male Sprague-Dawley rats housed in a 12 : 12 LD cycle resulted in increase pineal N-acetyltransferase (NAT) activity. Pargyline 75-84 N-acetyltransferase 1 Rattus norvegicus 197-200 6125331-5 1982 The administration of pargyline, a MAO inhibitor, which increased brain octopamine, resulted in a reduction of systolic blood pressure; and this decrease was greater after administration of octopamine precursors and PEA. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 35-38 6174485-6 1982 Omission of substrate from the incubation medium or pre-incubation with pargyline, a specific MAO inhibitor, drastically reduced the amount of deposits. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 94-97 7337495-7 1981 Pargyline, at a dose which significantly inhibited MAO and increased brain stem norepinephrine and dopamine levels, reduced the magnitude of the shock bradycardia. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 51-54 7335950-3 1981 Thus, incubation of DIP (10(-4) M) with rat liver mitochondria for 90 min demonstrated 74.8 +/- 4.1% metabolism which was almost completely blocked by the MAO inhibitor pargyline (10(-5) M). Pargyline 169-178 monoamine oxidase A Rattus norvegicus 155-158 7264664-2 1981 [3H]Pargyline was bound to MAO A in a crude mitochondrial fraction from the placental trophoblast of a male newborn and to MAO B in blood platelets from the umbilical vein of the same newborn. Pargyline 4-13 monoamine oxidase A Homo sapiens 27-32 7264664-2 1981 [3H]Pargyline was bound to MAO A in a crude mitochondrial fraction from the placental trophoblast of a male newborn and to MAO B in blood platelets from the umbilical vein of the same newborn. Pargyline 4-13 monoamine oxidase B Homo sapiens 123-128 7264664-6 1981 When SDS-solubilized, [3H]pargyline-labeled MAO A and B proteins from the same male newborn were subjected to limited proteolysis and one-dimensional peptide mapping in SDS gels, different patterns of [3H]pargyline-labeled peptides were obtained. Pargyline 26-35 monoamine oxidase A Homo sapiens 44-49 6265598-3 1981 An overall increase in the synthesis of gangliosides more complex than GM3 was also observed in the mouse neuroblastoma x hamster brain explant hybrid cell line NCB-20 following elevation of cyclic AMP levels by treatment with serotonin and pargyline. Pargyline 241-250 granulocyte macrophage antigen 3 Mus musculus 71-74 6219431-2 1982 The accumulation of p-chlorophenylethylamine (pCPE) in rat brain after administration of pargyline plus p-chlorophenylalanine (pCPA) is demonstrated. Pargyline 89-98 procollagen C-endopeptidase enhancer Rattus norvegicus 20-44 6219431-2 1982 The accumulation of p-chlorophenylethylamine (pCPE) in rat brain after administration of pargyline plus p-chlorophenylalanine (pCPA) is demonstrated. Pargyline 89-98 procollagen C-endopeptidase enhancer Rattus norvegicus 46-50 7219574-3 1981 Catechol-O-methyl transferase and monoamine oxidase were inhibited by 100 microM U-0521 and pargyline, respectively. Pargyline 92-101 catechol O-methyltransferase Cavia porcellus 0-29 6784898-0 1981 Studies on the pargyline-binding site of different types of monoamine oxidase. Pargyline 15-24 monoamine oxidase A Rattus norvegicus 60-77 6784898-3 1981 The [3H]pargyline-MAO adducts were isolated and hydrolyzed by proteolytic enzymes, and the labelled peptides (pargyline-binding sites) separated and compared by paper chromatography and by paper electrophoresis at various pH values. Pargyline 8-17 monoamine oxidase A Rattus norvegicus 18-21 6784898-8 1981 It is concluded that the primary structures immediately surrounding the pargyline-binding sites are identical for both type A and type B MAO in these tissues. Pargyline 72-81 monoamine oxidase A Rattus norvegicus 137-140 6907314-1 1980 Pretreatment of guinea pigs with paragyline (100 mg/kg i.p., 18 hr before sacrifice) resulted in a significant depression in the overflow of endogenous norepinephrine (NE), total 3H, [3H]NE and dopamine beta-hydroxylase associated with stimulation of the sympathetic nerves to the isolated heart. Pargyline 33-43 dopamine beta-hydroxylase Cavia porcellus 194-219 6791210-5 1981 Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline. Pargyline 78-87 monoamine oxidase B Homo sapiens 62-67 6791210-5 1981 Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline. Pargyline 202-211 monoamine oxidase A Homo sapiens 27-32 6791210-5 1981 Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline. Pargyline 202-211 monoamine oxidase B Homo sapiens 62-67 6252497-2 1980 Drugs which stimulate dopamine receptors (apomorphine or bromocriptine) or increase availability of dopamine (pargyline) inhibited the effect of beta-endorphin on plasma prolactin. Pargyline 110-119 proopiomelanocortin Homo sapiens 145-159 7424708-5 1980 We propose that the cytochrome P-450 catalyzed conversion of pargyline to its active metabolite, propiolaldehyde, proceeds via a mechanism involving N-depropargylation, viz., hydroxylation of pargyline alpha to the acetylenic bond forming a carbinolamine intermediate, followed by dissociation. Pargyline 192-201 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 20-36 6104592-1 1980 The administration of pargyline to normal rats enhanced the adrenal catecholamines noradrenaline + adrenaline content, tyrosine hydroxylase (TH) and catechol -0-methyl transferase (COMT) activity together with a reduction in monoamine oxidase (MAO) activity. Pargyline 22-31 catechol-O-methyltransferase Rattus norvegicus 181-185 6104592-1 1980 The administration of pargyline to normal rats enhanced the adrenal catecholamines noradrenaline + adrenaline content, tyrosine hydroxylase (TH) and catechol -0-methyl transferase (COMT) activity together with a reduction in monoamine oxidase (MAO) activity. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 225-242 6104592-1 1980 The administration of pargyline to normal rats enhanced the adrenal catecholamines noradrenaline + adrenaline content, tyrosine hydroxylase (TH) and catechol -0-methyl transferase (COMT) activity together with a reduction in monoamine oxidase (MAO) activity. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 244-247 523771-0 1979 Further characterization of the inhibition of aldehyde dehydrogenase activity by pargyline. Pargyline 81-90 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 46-68 7349975-3 1980 Also, beta-endorphin blunted the pargyline-induced accumulation of hypothalamic dopamine. Pargyline 33-42 proopiomelanocortin Homo sapiens 6-20 6785574-3 1980 Acetylenic amines as exemplified by clorgyline, deprenyl and pargyline are called "suicide inhibitors" because an irreversible inhibitor is formed by the action of MAO from a relatively innocuous compound which acts as a substrate. Pargyline 61-70 monoamine oxidase A Rattus norvegicus 164-167 6785574-7 1980 A comparison of the inhibitory effects of clorgyline, deprenyl and pargyline on liver enzyme preparations from bovine or rat have confirmed our expectation that these irreversible inactivators form the same type of adduct with the cysteinyl-flavin active site of MAO "type A" and "type B", and that binding is stoichiometric at the N-5 of the covalently bound flavin in a flavocyanine linkage. Pargyline 67-76 monoamine oxidase A Rattus norvegicus 263-266 523771-1 1979 The in vivo inhibition of low Km mitochondrial aldehyde dehydrogenase (AlDH) activity by pargyline was not maximal until more than 30 minutes after i.p. Pargyline 89-98 aldehyde dehydrogenase 2 family member Rattus norvegicus 33-69 523771-1 1979 The in vivo inhibition of low Km mitochondrial aldehyde dehydrogenase (AlDH) activity by pargyline was not maximal until more than 30 minutes after i.p. Pargyline 89-98 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 71-75 523771-5 1979 Injection of pargyline inhibited low Km mitochondrial AlDH activity more in males than in females. Pargyline 13-22 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 54-58 523771-6 1979 Incubation of rat liver microsomes with an NADPH-generating system and pargyline produced an in vitro inhibitor of low Km mitochondrial AlDH activity. Pargyline 71-80 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 136-140 523771-7 1979 Pretreatment of rats with phenobarbital increased the AlDH inhibitor produced by incubation of their microsomes with pargyline. Pargyline 117-126 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 54-58 477738-1 1979 The monoamine oxidase (MAO) inhibitor pargyline induced a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. Pargyline 38-47 monoamine oxidase A Rattus norvegicus 4-21 477738-1 1979 The monoamine oxidase (MAO) inhibitor pargyline induced a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. Pargyline 38-47 monoamine oxidase A Rattus norvegicus 23-26 523336-7 1979 This action of viloxazine was abolished by cyproheptadine but potentiated by pargyline, an inhibitor of MAO. Pargyline 77-86 monoamine oxidase A Rattus norvegicus 104-107 119887-4 1979 The TRH-induced hyperactivity was remarkably suppressed by alpha-methyltyrosine and in contrast, augmented by pargyline. Pargyline 110-119 thyrotropin releasing hormone Rattus norvegicus 4-7 111275-0 1979 Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Pargyline 30-39 monoamine oxidase A Homo sapiens 57-83 111275-2 1979 During a similar 4-week crossover treatment period with pargyline, a selective MAO-B inhibitor, platelet MAO activity was essentially completely inhibited in the same individuals. Pargyline 56-65 monoamine oxidase B Homo sapiens 79-84 573894-2 1979 Serotonin (5-HT) agonists, L-tryptophan or 5-hydroxytryptophan and a MAO inhibitor, pargyline, suppressed the APO-induced aggressiveness. Pargyline 84-93 monoamine oxidase A Rattus norvegicus 69-72 7424708-0 1980 Microsomal N-depropargylation of pargyline to propiolaldehyde, an irreversible inhibitor of mitochondrial aldehyde dehydrogenase. Pargyline 33-42 aldehyde dehydrogenase 2 family member Rattus norvegicus 92-128 684076-1 1978 When administered by intraperitoneal injection daily for 3, 7 or 14 days, pargyline (75 mg/kg) significantly reduced rat hepatic microsomal ethylmorphine N-demethylase activity and cytochrome P-450 content. Pargyline 74-83 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 181-197 7424708-1 1980 Rat liver microsomes catalyzed the conversion of pargyline (N-methyl-N-propargylbenzylamine) to propiolaldehyde, a potent inhibitor of the low Km mitochondrial aldehyde dehydrogenase (AlDH) isozyme. Pargyline 49-58 aldehyde dehydrogenase 2 family member Rattus norvegicus 146-182 7424708-1 1980 Rat liver microsomes catalyzed the conversion of pargyline (N-methyl-N-propargylbenzylamine) to propiolaldehyde, a potent inhibitor of the low Km mitochondrial aldehyde dehydrogenase (AlDH) isozyme. Pargyline 49-58 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 184-188 7424708-1 1980 Rat liver microsomes catalyzed the conversion of pargyline (N-methyl-N-propargylbenzylamine) to propiolaldehyde, a potent inhibitor of the low Km mitochondrial aldehyde dehydrogenase (AlDH) isozyme. Pargyline 60-91 aldehyde dehydrogenase 2 family member Rattus norvegicus 146-182 7424708-1 1980 Rat liver microsomes catalyzed the conversion of pargyline (N-methyl-N-propargylbenzylamine) to propiolaldehyde, a potent inhibitor of the low Km mitochondrial aldehyde dehydrogenase (AlDH) isozyme. Pargyline 60-91 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 184-188 7424708-2 1980 The involvement of cytochrome P-450 in vivo was shown indirectly by (a) the ability of SKF-525A to block pargyline-induced acetaldehydemia, (b) the prolongation of phenobarbital sleeping time by pargyline, and (c) the enhancement of pargyline-induced acetaldehydemia by phenobarbital pretreatment. Pargyline 105-114 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 19-35 7424708-2 1980 The involvement of cytochrome P-450 in vivo was shown indirectly by (a) the ability of SKF-525A to block pargyline-induced acetaldehydemia, (b) the prolongation of phenobarbital sleeping time by pargyline, and (c) the enhancement of pargyline-induced acetaldehydemia by phenobarbital pretreatment. Pargyline 195-204 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 19-35 7424708-2 1980 The involvement of cytochrome P-450 in vivo was shown indirectly by (a) the ability of SKF-525A to block pargyline-induced acetaldehydemia, (b) the prolongation of phenobarbital sleeping time by pargyline, and (c) the enhancement of pargyline-induced acetaldehydemia by phenobarbital pretreatment. Pargyline 195-204 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 19-35 7424708-5 1980 We propose that the cytochrome P-450 catalyzed conversion of pargyline to its active metabolite, propiolaldehyde, proceeds via a mechanism involving N-depropargylation, viz., hydroxylation of pargyline alpha to the acetylenic bond forming a carbinolamine intermediate, followed by dissociation. Pargyline 61-70 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 20-36 499103-1 1979 Rat thyroid monoamine oxidase (MAO) was inhibited by the non-hydrazine derivatives paragyline and tranylcypromine to a higher degree than the hydrazine derivative iproniazide. Pargyline 83-93 monoamine oxidase A Rattus norvegicus 12-29 499103-1 1979 Rat thyroid monoamine oxidase (MAO) was inhibited by the non-hydrazine derivatives paragyline and tranylcypromine to a higher degree than the hydrazine derivative iproniazide. Pargyline 83-93 monoamine oxidase A Rattus norvegicus 31-34 705026-0 1978 Inhibition of aldehyde dehydrogenase by propiolaldehyde, a possible metabolite of pargyline. Pargyline 82-91 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 14-36 705026-1 1978 Pargyline (Eutonyl) inhibited aldehyde dehydrogenase (AlDH) in vivo in rats as adduced by the elevation of ethanol-derived blood acetaldehyde (AcH), but had no effect in vitro on the enzyme in intact mitochondria. Pargyline 0-9 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 30-52 705026-1 1978 Pargyline (Eutonyl) inhibited aldehyde dehydrogenase (AlDH) in vivo in rats as adduced by the elevation of ethanol-derived blood acetaldehyde (AcH), but had no effect in vitro on the enzyme in intact mitochondria. Pargyline 0-9 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 54-58 705026-2 1978 SKF-525A, an inhibitor of the hepatic microsomal P-450 enzyme system, completely prevented the pargyline-induced elevation of blood AcH in vivo, further implicating a metabolite of pargyline as the active inhibitor of AlDH. Pargyline 95-104 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 218-222 705026-2 1978 SKF-525A, an inhibitor of the hepatic microsomal P-450 enzyme system, completely prevented the pargyline-induced elevation of blood AcH in vivo, further implicating a metabolite of pargyline as the active inhibitor of AlDH. Pargyline 181-190 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 218-222 705026-3 1978 Of the potential pargyline metabolites tested, N-benzylpropargylamine and propargyl alcohol--like pargyline itself--readily inhibited AlDH in vivo but were without effect on the enzyme in vitro. Pargyline 17-26 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 134-138 705026-3 1978 Of the potential pargyline metabolites tested, N-benzylpropargylamine and propargyl alcohol--like pargyline itself--readily inhibited AlDH in vivo but were without effect on the enzyme in vitro. Pargyline 98-107 aldehyde dehydrogenase 3 family, member A1 Rattus norvegicus 134-138 673014-13 1978 Inhibition of monoamine oxidase (MAO) by pargyline increased the extraneuronal formation of NMN; MAO and catechol-O-methyl transferase (COMT) appear to be contained in the same extraneuronal compartment. Pargyline 41-50 monoamine oxidase A Rattus norvegicus 14-31 673014-13 1978 Inhibition of monoamine oxidase (MAO) by pargyline increased the extraneuronal formation of NMN; MAO and catechol-O-methyl transferase (COMT) appear to be contained in the same extraneuronal compartment. Pargyline 41-50 monoamine oxidase A Rattus norvegicus 33-36 21126-5 1977 At 100% oxygen concentration, pargyline showed the most potent inhibition of MAO activity in liver mitochondria with tyramine as substrate, but inhibitions caused by pheniprazine and harmaline were not remarkable. Pargyline 30-39 monoamine oxidase A Rattus norvegicus 77-80 854089-0 1977 N-acetyltransferase activity in pineal gland of rats treated with pargyline. Pargyline 66-75 N-acetyltransferase 1 Rattus norvegicus 0-19 21126-6 1977 At 100% oxygen concentration, harmaline showed the most potent inhibition of MAO activity in the liver when serotonin served as substrate, while inhibitions of the MAO activity by pargyline and pheniprazine were weak. Pargyline 180-189 monoamine oxidase A Rattus norvegicus 164-167 21126-9 1977 Pargyline revealed a noncompetitive inhibition to MAO activity in liver and brain with tyramine and serotonin as substrate, harmaline a competitive inhibition to MAO activity in liver and brain with tyramine as substrate, while noncompetitive inhibition to MAO activity in liver and brain was evident when serotonin was used as the substrate. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 50-53 854089-1 1977 After injection of 20 mg/kg of the monoamine oxidase inhibitor pargyline every other day up to 9 days, the activity of N-acetyltransferase (NAT) in the pineal gland of rats remained unchanged during the light-period. Pargyline 63-72 N-acetyltransferase 1 Rattus norvegicus 119-138 854089-1 1977 After injection of 20 mg/kg of the monoamine oxidase inhibitor pargyline every other day up to 9 days, the activity of N-acetyltransferase (NAT) in the pineal gland of rats remained unchanged during the light-period. Pargyline 63-72 N-acetyltransferase 1 Rattus norvegicus 140-143 1067888-0 1976 Effects of reserpine and pargyline on glutamate decarboxylase activity in rat hypothalamic nuclei. Pargyline 25-34 glutamate-ammonia ligase Rattus norvegicus 38-61 955982-1 1976 The presence of aromatic 1-amino acid decarboxylase (AADC) in nerve cell bodies of the intrinsic plexuses of the guinea-pig small intestine was demonstrated by incubating segments of intestine with 1-dopa in the presence of an inhibitor of monoamine oxidase, pargyline. Pargyline 259-268 aromatic-L-amino-acid decarboxylase Cavia porcellus 53-57 1012333-3 1976 In rats treated with pargyline (50 mg/kg s.c.), the half-lives of recovery of striatal MAO activity and normal endogenous contents of homovanillic and 3,4-dihydroxyphenylacetic acids in striatum ranged from 9 to 14 days. Pargyline 21-30 monoamine oxidase A Rattus norvegicus 87-90 12389-8 1976 The pI curves for inhibition of MAO activity by harmine, pargyline and iproniazid were similar and almost the same pI 50 values for the respective inhibitors were obtained with the two substrates. Pargyline 57-66 monoamine oxidase A Rattus norvegicus 32-35 1012333-6 1976 Recovery from this effect of pargyline, however, was more rapid with a half-life of 15-19 h. Similar changes were observed when 3H-DOPA or 3H-dopamine was injected intracisternally, indicating that the phenomenon did not take place in the cerebral blood capillary walls, which are known to contain DOPA decarboxylase and MAO activities. Pargyline 29-38 monoamine oxidase A Rattus norvegicus 321-324 1012333-8 1976 was 3H-homovanillic acid, which was strongly reduced 2 h after pargyline, but normalized after 24 h of pretreatment with the MAO inhibitor. Pargyline 63-72 monoamine oxidase A Rattus norvegicus 125-128 1012333-10 1976 Moreover, in an experiment in which the animals were pretreated with pargyline at various times up to 21 days, a second injection of the MAO inhibitor 1.5 h before 3H-DOPA restored the increase in 3H-DA + 3H-MT observed with a single treatment with pargyline 1.5 h before the labelled amino acid. Pargyline 69-78 monoamine oxidase A Rattus norvegicus 137-140 1012333-10 1976 Moreover, in an experiment in which the animals were pretreated with pargyline at various times up to 21 days, a second injection of the MAO inhibitor 1.5 h before 3H-DOPA restored the increase in 3H-DA + 3H-MT observed with a single treatment with pargyline 1.5 h before the labelled amino acid. Pargyline 249-258 monoamine oxidase A Rattus norvegicus 137-140 1012333-12 1976 The threshold dose of pargyline for producing the short-term effect was about 10 times higher than that for an overall MAO (DA deaminating) inhibition. Pargyline 22-31 monoamine oxidase A Rattus norvegicus 119-122 1012333-14 1976 The data reported suggest the existence of a small portion of an additional form of MAO with a rapid turnover and with a marked capacity to deaminate dopamine or methoxytyramine, and a greater resistance to inhibition by pargyline than cerebral MAO in general. Pargyline 221-230 monoamine oxidase A Rattus norvegicus 84-87 956156-3 1976 The disappearance of PEA was completely inhibited by pargyline, a potent inhibitor of MAO. Pargyline 53-62 monoamine oxidase A Rattus norvegicus 86-89 1116620-5 1975 Pargyline possibly acts by decreasing MAO levels which, in turn, may increase potentially damaging amines which may be responsible for the testicular damage. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 38-41 1143390-0 1975 Proceedings: Age dependent recovery of rat brain MAO activity after administration of a single dose of iproniazid and pargyline. Pargyline 118-127 monoamine oxidase A Rattus norvegicus 49-52 33214844-4 2020 PET imaging studies in rats demonstrated that both [11C]COU and [11C]PHXY exhibit retention in cardiac tissues that can be blocked by pretreatment with the MAO inhibitors deprenyl (MAO-B) and pargyline (MAO-A and -B). Pargyline 192-201 monoamine oxidase A Rattus norvegicus 156-159 32719542-5 2020 Structure-based modelling identified the U.S. Food and Drug Administration-approved drug pargyline as a potential RNLS inhibitor. Pargyline 89-98 renalase, FAD-dependent amine oxidase Mus musculus 114-118 33353806-2 2021 All the compounds exhibited excellent iron-chelating activities (pFe3+ = 14.8-19.2) and showed favorable monoamine oxidase B (MAO-B) inhibitory effects compared to the reference drug Pargyline (IC50 = 86.9 nM). Pargyline 183-192 monoamine oxidase B Rattus norvegicus 105-124 33353806-2 2021 All the compounds exhibited excellent iron-chelating activities (pFe3+ = 14.8-19.2) and showed favorable monoamine oxidase B (MAO-B) inhibitory effects compared to the reference drug Pargyline (IC50 = 86.9 nM). Pargyline 183-192 monoamine oxidase B Rattus norvegicus 126-131 33085988-2 2021 The result indicated that 7,8-dihydroxy-3-(4-nitrophenyl)coumarin (3j) was most effective against MAO-A (inhibition concentration [IC50 ] = 6.46 +- 0.02 microM) and MAO-B (IC50 = 3.8 +- 0.3 microM) enzymes than other synthesized compounds and reference compounds (pargyline and moclobemide). Pargyline 265-274 monoamine oxidase A Homo sapiens 98-103 33214844-4 2020 PET imaging studies in rats demonstrated that both [11C]COU and [11C]PHXY exhibit retention in cardiac tissues that can be blocked by pretreatment with the MAO inhibitors deprenyl (MAO-B) and pargyline (MAO-A and -B). Pargyline 192-201 monoamine oxidase A Rattus norvegicus 203-215 32392202-0 2020 [Pargyline and r-Chlorophenylalanine Decrease Expression of Ptpn5 Encoding Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in the Mouse Striatum]. Pargyline 1-10 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 60-65 32847068-7 2020 We found that pargyline, known as a LSD1 inhibitor, can reduce AR activity in kidney cancer cells. Pargyline 14-23 lysine (K)-specific demethylase 1A Mus musculus 36-40 32847068-7 2020 We found that pargyline, known as a LSD1 inhibitor, can reduce AR activity in kidney cancer cells. Pargyline 14-23 androgen receptor Mus musculus 63-65 32392202-14 2020 Thus, a new method was proposed to study the STEP activity in the brain and p-chlorophenylalanine and pargyline were shown to decrease Ptpn5 expression in the striatum in mice. Pargyline 102-111 protein tyrosine phosphatase, non-receptor type 5 Mus musculus 135-140 26953687-4 2016 The effect of local administration of a MAO inhibitor, pargyline, was investigated. Pargyline 55-64 monoamine oxidase A Rattus norvegicus 40-43 31534138-8 2019 Combinatorial use of CtBP inhibitors with the LSD1 inhibitor pargyline has synergistic influence. Pargyline 61-70 lysine demethylase 1A Homo sapiens 46-50 28685208-5 2017 In addition, iron-induced increase in MAO-B probe fluorescence could be prevented by pargyline and other newly developed MAO-B inhibitors, suggesting that it was MAO-B activity-dependent. Pargyline 85-94 monoamine oxidase B Homo sapiens 38-43 28377178-4 2017 As such, KDM1A inhibitors, such as pargyline and GSK2879552, dramatically suppress stem-like properties of sorafenib-resistant HCC cells. Pargyline 35-44 lysine demethylase 1A Homo sapiens 9-14 29032766-6 2017 Pargyline did not inhibit OATP1B1 or OATP1B3, but weakly inhibited OCT1 and OCT3. Pargyline 0-9 solute carrier family 22 member 1 Homo sapiens 67-71 29032766-6 2017 Pargyline did not inhibit OATP1B1 or OATP1B3, but weakly inhibited OCT1 and OCT3. Pargyline 0-9 POU class 5 homeobox 1 Homo sapiens 76-80 29911787-1 2017 This study was designed to investigate effects of pargyline on histone methylation in the promoter and enhancer regions and transcription of cytochrome P450 3A4/3A7 (CYP3A4/3A7) gene. Pargyline 50-59 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 166-176 29911787-11 2017 The level of CYP3A7 was markedly enhanced in human primary fetal liver cells by treatment with 1.2, 2.4 mmol L(-1) of pargyline (P < 0.05, P < 0.01) and the levels of CYP3A4/3A7 were remarkably enhanced by treatment with 3 mmol L(-1) of pargyline in HepG2 cells (P < 0.001) compared with solvent control. Pargyline 118-127 cytochrome P450 family 3 subfamily A member 7 Homo sapiens 13-19 29911787-11 2017 The level of CYP3A7 was markedly enhanced in human primary fetal liver cells by treatment with 1.2, 2.4 mmol L(-1) of pargyline (P < 0.05, P < 0.01) and the levels of CYP3A4/3A7 were remarkably enhanced by treatment with 3 mmol L(-1) of pargyline in HepG2 cells (P < 0.001) compared with solvent control. Pargyline 118-127 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 173-179 29911787-11 2017 The level of CYP3A7 was markedly enhanced in human primary fetal liver cells by treatment with 1.2, 2.4 mmol L(-1) of pargyline (P < 0.05, P < 0.01) and the levels of CYP3A4/3A7 were remarkably enhanced by treatment with 3 mmol L(-1) of pargyline in HepG2 cells (P < 0.001) compared with solvent control. Pargyline 243-252 cytochrome P450 family 3 subfamily A member 7 Homo sapiens 13-19 29911787-14 2017 In conclusion, the enriched H3K4me2 in the promoter and enhancer regions was induced by pargyline with HNF4A or GR binding site in CYP3A4/3A7 gene to activate the corresponding genes. Pargyline 88-97 hepatocyte nuclear factor 4 alpha Homo sapiens 103-108 29911787-14 2017 In conclusion, the enriched H3K4me2 in the promoter and enhancer regions was induced by pargyline with HNF4A or GR binding site in CYP3A4/3A7 gene to activate the corresponding genes. Pargyline 88-97 nuclear receptor subfamily 3 group C member 1 Homo sapiens 112-114 29911787-14 2017 In conclusion, the enriched H3K4me2 in the promoter and enhancer regions was induced by pargyline with HNF4A or GR binding site in CYP3A4/3A7 gene to activate the corresponding genes. Pargyline 88-97 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-137 28058134-3 2016 Here, we investigated pargyline, an inhibitor of lysine-specific demethylase 1 (LSD1), which mainly catalyzes the demethylation of the di- and mono-methylation of H3K4. Pargyline 22-31 lysine demethylase 1A Homo sapiens 49-78 28058134-3 2016 Here, we investigated pargyline, an inhibitor of lysine-specific demethylase 1 (LSD1), which mainly catalyzes the demethylation of the di- and mono-methylation of H3K4. Pargyline 22-31 lysine demethylase 1A Homo sapiens 80-84 26830512-6 2016 However, following administration of a peripheral AADC inhibitor (carbidopa) with or without a monoamine oxidase inhibitor (pargyline) co-application, systemic administration of l-dopa resulted in ~94% of AADC cells becoming DA-immunopositive in the spinal cord below the lesion, whereas in normal or sham-operated rats none or very few of AADC cells became DA-immunopositive with the same treatment. Pargyline 124-133 dopa decarboxylase Rattus norvegicus 205-209 26830512-6 2016 However, following administration of a peripheral AADC inhibitor (carbidopa) with or without a monoamine oxidase inhibitor (pargyline) co-application, systemic administration of l-dopa resulted in ~94% of AADC cells becoming DA-immunopositive in the spinal cord below the lesion, whereas in normal or sham-operated rats none or very few of AADC cells became DA-immunopositive with the same treatment. Pargyline 124-133 dopa decarboxylase Rattus norvegicus 205-209 31362921-5 2019 We report the design and synthesis of the first tool compounds as PYCR1 inhibitors, derived from pargyline, which were assayed to assess their ability to attenuate the production of proline. Pargyline 97-106 pyrroline-5-carboxylate reductase 1 Homo sapiens 66-71 25656918-3 2015 The results from single point time dependent inhibition and shift assays suggest that clorgyline, pargyline, phenelzine, and selegiline were metabolism based inhibitors of CYP2B6. Pargyline 98-107 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 172-178 26872725-6 2016 Moreover, treatments of LSD1 chemical inhibitors (pargyline and tranylcypromine) induced its protein reduction probably via enhanced protein degradation and produced similar phenotypic changes resembling LSD1 silencing in OSCC cells. Pargyline 50-59 lysine demethylase 1A Homo sapiens 24-28 26872725-6 2016 Moreover, treatments of LSD1 chemical inhibitors (pargyline and tranylcypromine) induced its protein reduction probably via enhanced protein degradation and produced similar phenotypic changes resembling LSD1 silencing in OSCC cells. Pargyline 50-59 lysine demethylase 1A Homo sapiens 204-208 26780349-9 2016 5-MeO-DMT (1mg/kg) had no effect on PPI when tested 45-min post-injection but disrupted PPI in animals pretreated with the MAO-A inhibitor clorgyline or the MAO-A/B inhibitor pargyline. Pargyline 175-184 monoamine oxidase A Rattus norvegicus 157-162 26435505-0 2015 Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Pargyline 22-31 lysine demethylase 1A Homo sapiens 14-18 26435505-4 2015 This study examined the effect of Pargyline (an inhibitor of LSD1) on the process of EMT in vitro and in vivo. Pargyline 34-43 lysine demethylase 1A Homo sapiens 61-65 26263056-7 2015 The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as beta-carboline alkaloids from Peganum harmala. Pargyline 131-140 monoamine oxidase A Homo sapiens 67-72 26263056-7 2015 The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as beta-carboline alkaloids from Peganum harmala. Pargyline 131-140 monoamine oxidase B Homo sapiens 77-82 25936509-7 2015 The irreversible MAO-B inhibitor Pargyline (65 mg/kg) failed to accumulate N(tau)-MHA in the hypothalamus. Pargyline 33-42 monoamine oxidase B Rattus norvegicus 17-22 25656918-4 2015 In IC50 shift assays, clorgyline, pargyline, phenelzine and selegiline are metabolism based inhibitors of CYP2B6 with fold shit of 3.0-, 3.7-, 2.9-, and 11.4-fold respectively. Pargyline 34-43 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 106-112 25627913-3 2015 Furthermore, LNCap cell line was treated with Pargyline (an inhibitor of LSD1), and Western blot was used to analyze LSD1 and E-cadherin expression. Pargyline 46-55 lysine demethylase 1A Homo sapiens 73-77 25637699-6 2015 Monoamine aldehyde mediation of the oligomerization was assessed using the MAO inhibitor, pargyline. Pargyline 90-99 monoamine oxidase A Rattus norvegicus 75-78 25637699-8 2015 In synuclein overexpressing PC12 cells, levodopa and 5-hydroxytryptophan elicited pargyline-sensitive alpha-synuclein oligomerization. Pargyline 82-91 synuclein alpha Rattus norvegicus 102-117 25627913-9 2015 Moreover, Pargyline inhibited activity of LSD1 and up-regulated E-cadherin expression. Pargyline 10-19 lysine demethylase 1A Homo sapiens 42-46 25627913-9 2015 Moreover, Pargyline inhibited activity of LSD1 and up-regulated E-cadherin expression. Pargyline 10-19 cadherin 1 Homo sapiens 64-74 23581564-8 2014 The MAO-B inhibitor pargyline completely offset this change, suggesting that MAO activation induces a latent mitochondrial dysfunction, causing these organelles to hydrolyze ATP. Pargyline 20-29 monoamine oxidase B Mus musculus 4-9 24800755-7 2015 Furthermore, Con A-activated T cells treated with pargyline produced a lower level of IFN-gamma and a higher level of IL-4 than the control group. Pargyline 50-59 interferon gamma Mus musculus 86-95 24800755-7 2015 Furthermore, Con A-activated T cells treated with pargyline produced a lower level of IFN-gamma and a higher level of IL-4 than the control group. Pargyline 50-59 interleukin 4 Mus musculus 118-122 24800755-4 2015 RESULTS: Pargyline downregulated the expression of Th1-relative factors, T-bet, interferon (IFN)-gamma and interleukin (IL)-2, but upregulated the expression of Th2-relative factors, GATA-3, IL-4 and IL-10. Pargyline 9-18 interleukin 2 Mus musculus 107-125 24800755-4 2015 RESULTS: Pargyline downregulated the expression of Th1-relative factors, T-bet, interferon (IFN)-gamma and interleukin (IL)-2, but upregulated the expression of Th2-relative factors, GATA-3, IL-4 and IL-10. Pargyline 9-18 GATA binding protein 3 Mus musculus 183-189 24800755-4 2015 RESULTS: Pargyline downregulated the expression of Th1-relative factors, T-bet, interferon (IFN)-gamma and interleukin (IL)-2, but upregulated the expression of Th2-relative factors, GATA-3, IL-4 and IL-10. Pargyline 9-18 interleukin 4 Mus musculus 191-195 24800755-4 2015 RESULTS: Pargyline downregulated the expression of Th1-relative factors, T-bet, interferon (IFN)-gamma and interleukin (IL)-2, but upregulated the expression of Th2-relative factors, GATA-3, IL-4 and IL-10. Pargyline 9-18 interleukin 10 Mus musculus 200-205 24800755-5 2015 Pargyline reduced the percentage of IFN-gamma-producing CD4+ cells and the CD4+IFN-gamma+/CD4+IL-4+ cell ratio, although it did not alter the proportion of IL-4-producing CD4+ cells. Pargyline 0-9 interferon gamma Mus musculus 36-45 24800755-5 2015 Pargyline reduced the percentage of IFN-gamma-producing CD4+ cells and the CD4+IFN-gamma+/CD4+IL-4+ cell ratio, although it did not alter the proportion of IL-4-producing CD4+ cells. Pargyline 0-9 CD4 antigen Mus musculus 75-88 24800755-5 2015 Pargyline reduced the percentage of IFN-gamma-producing CD4+ cells and the CD4+IFN-gamma+/CD4+IL-4+ cell ratio, although it did not alter the proportion of IL-4-producing CD4+ cells. Pargyline 0-9 interleukin 4 Mus musculus 94-98 24886859-10 2014 Treatment with tranylcypromine and pargyline, which are potent inhibitors of LSD1, prevented IL-1beta-induced H3K9 demethylation at the mPGES-1 promoter and expression of mPGES-1. Pargyline 35-44 lysine demethylase 1A Homo sapiens 77-81 24886859-10 2014 Treatment with tranylcypromine and pargyline, which are potent inhibitors of LSD1, prevented IL-1beta-induced H3K9 demethylation at the mPGES-1 promoter and expression of mPGES-1. Pargyline 35-44 interleukin 1 beta Homo sapiens 93-101 24886859-10 2014 Treatment with tranylcypromine and pargyline, which are potent inhibitors of LSD1, prevented IL-1beta-induced H3K9 demethylation at the mPGES-1 promoter and expression of mPGES-1. Pargyline 35-44 prostaglandin E synthase Mus musculus 136-143 24886859-10 2014 Treatment with tranylcypromine and pargyline, which are potent inhibitors of LSD1, prevented IL-1beta-induced H3K9 demethylation at the mPGES-1 promoter and expression of mPGES-1. Pargyline 35-44 prostaglandin E synthase Mus musculus 171-178 23271029-8 2013 Moreover, the 5-HT-induced expression of PPARgamma-responsive genes (PEPCK, aP2/FABP4) was blocked by GW 9662, a PPARgamma-inhibitor, or by pargyline, a MAO-inhibitor. Pargyline 140-149 peroxisome proliferator activated receptor gamma Homo sapiens 41-50 24165091-13 2013 Chemical LSD1 inhibition induced cytotoxicity in ovarian cancer lines, which roughly correlated with their reported LSD1 inhibitory potential (RN-1,S2101 >> pargyline,TCP). Pargyline 163-172 lysine demethylase 1A Homo sapiens 9-13 24080403-5 2013 MAO-B inhibitor pargyline (15mg/kg) was systemically administered before neurotoxin administration. Pargyline 16-25 monoamine oxidase B Rattus norvegicus 0-5 23271029-8 2013 Moreover, the 5-HT-induced expression of PPARgamma-responsive genes (PEPCK, aP2/FABP4) was blocked by GW 9662, a PPARgamma-inhibitor, or by pargyline, a MAO-inhibitor. Pargyline 140-149 phosphoenolpyruvate carboxykinase 2, mitochondrial Homo sapiens 69-74 23271029-8 2013 Moreover, the 5-HT-induced expression of PPARgamma-responsive genes (PEPCK, aP2/FABP4) was blocked by GW 9662, a PPARgamma-inhibitor, or by pargyline, a MAO-inhibitor. Pargyline 140-149 fatty acid binding protein 4 Homo sapiens 76-79 23271029-8 2013 Moreover, the 5-HT-induced expression of PPARgamma-responsive genes (PEPCK, aP2/FABP4) was blocked by GW 9662, a PPARgamma-inhibitor, or by pargyline, a MAO-inhibitor. Pargyline 140-149 fatty acid binding protein 4 Homo sapiens 80-85 23196068-10 2013 The MAO inhibitor, pargyline, also attenuated cell death and ROS after l-dopa treatment. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 4-7 23499958-6 2013 The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation. Pargyline 57-66 monoamine oxidase A Homo sapiens 23-28 23499958-6 2013 The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation. Pargyline 57-66 monoamine oxidase B Homo sapiens 33-38 23499958-6 2013 The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation. Pargyline 57-66 protein phosphatase 1 regulatory inhibitor subunit 1B Homo sapiens 117-125 22493729-11 2012 Interruption of LSD1 using siRNA or a chemical inhibitor, pargyline, suppressed proliferation, migration and invasion of A549, H460 and 293T cells. Pargyline 58-67 lysine demethylase 1A Homo sapiens 16-20 23258538-7 2013 MPTP-mediated toxicity in primary dopaminergic neurons was attenuated by CYP2D6 inhibitor, quinidine, and also partly by monoamine oxidase B inhibitors deprenyl and pargyline. Pargyline 165-174 monoamine oxidase B Mus musculus 121-140 23095308-8 2013 Meanwhile, the treatment with pargyline downregulated expression of T-bet and IFN-gamma but upregulated expression of GATA-3 and IL-4 in these lymphocytes. Pargyline 30-39 T-box 21 Mus musculus 68-73 23095308-8 2013 Meanwhile, the treatment with pargyline downregulated expression of T-bet and IFN-gamma but upregulated expression of GATA-3 and IL-4 in these lymphocytes. Pargyline 30-39 interferon gamma Mus musculus 78-87 23095308-8 2013 Meanwhile, the treatment with pargyline downregulated expression of T-bet and IFN-gamma but upregulated expression of GATA-3 and IL-4 in these lymphocytes. Pargyline 30-39 GATA binding protein 3 Mus musculus 118-124 23095308-8 2013 Meanwhile, the treatment with pargyline downregulated expression of T-bet and IFN-gamma but upregulated expression of GATA-3 and IL-4 in these lymphocytes. Pargyline 30-39 interleukin 4 Mus musculus 129-133 21452019-4 2012 We also demonstrated that inhibition of LSD1 activity by a pharmacological inhibitor, pargyline, or siRNA resulted in increased acetylation of H3K9 (AcH3K9). Pargyline 86-95 lysine demethylase 1A Homo sapiens 40-44 20667995-7 2011 RESULTS: We observed, 28 days after pargyline-mediated blockade of MAO (before or after IR), improved renal function as well as a net decrease in renal inflammation associated to lower IL-1beta and TNF-alpha gene expression. Pargyline 36-45 interleukin 1 beta Homo sapiens 185-193 21341713-0 2011 Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Pargyline 108-117 monoamine oxidase A Rattus norvegicus 22-48 21341713-1 2011 TEMPO-substituted pargyline analogues differentially inhibit recombinant human monoamine oxidase A (MAO A) and B (MAO B) in intact yeast mitochondria, suggesting these membrane-bound enzymes are located on differing faces of the mitochondrial outer membrane [Upadhyay, A., and Edmondson, D. E. (2009) Biochemistry 48, 3928]. Pargyline 18-27 monoamine oxidase A Homo sapiens 79-98 21341713-1 2011 TEMPO-substituted pargyline analogues differentially inhibit recombinant human monoamine oxidase A (MAO A) and B (MAO B) in intact yeast mitochondria, suggesting these membrane-bound enzymes are located on differing faces of the mitochondrial outer membrane [Upadhyay, A., and Edmondson, D. E. (2009) Biochemistry 48, 3928]. Pargyline 18-27 monoamine oxidase A Homo sapiens 100-105 21341713-1 2011 TEMPO-substituted pargyline analogues differentially inhibit recombinant human monoamine oxidase A (MAO A) and B (MAO B) in intact yeast mitochondria, suggesting these membrane-bound enzymes are located on differing faces of the mitochondrial outer membrane [Upadhyay, A., and Edmondson, D. E. (2009) Biochemistry 48, 3928]. Pargyline 18-27 monoamine oxidase B Homo sapiens 114-119 21341713-5 2011 In intact yeast mitochondria, recombinant rat MAO B is inhibited by the pargyline analogue whereas MAO A activity shows no inhibition. Pargyline 72-81 monoamine oxidase B Rattus norvegicus 46-51 22036763-3 2011 In this study, we found that Sp1 could be methylated and that methylation was maintained by treatment with pargyline, a lysine-specific demethylase 1 (LSD1) inhibitor or knock LSD1 down directly. Pargyline 107-116 lysine demethylase 1A Homo sapiens 120-149 22036763-3 2011 In this study, we found that Sp1 could be methylated and that methylation was maintained by treatment with pargyline, a lysine-specific demethylase 1 (LSD1) inhibitor or knock LSD1 down directly. Pargyline 107-116 lysine demethylase 1A Homo sapiens 151-155 20667995-7 2011 RESULTS: We observed, 28 days after pargyline-mediated blockade of MAO (before or after IR), improved renal function as well as a net decrease in renal inflammation associated to lower IL-1beta and TNF-alpha gene expression. Pargyline 36-45 tumor necrosis factor Homo sapiens 198-207 20716577-4 2010 Pargyline, an MAO inhibitor, reduced ROS accumulation along with a beneficial effect on the dystrophic phenotype of Col6a1(-/-) mice, a model of Bethlem myopathy and Ullrich congenital MD, and mdx mice, a model of Duchenne MD. Pargyline 0-9 collagen, type VI, alpha 1 Mus musculus 116-122 20833138-7 2010 Interruption of demethylase activity of LSD1 using shRNA or chemical inhibitor, pargyline, treatment led to aberrant histone codes on myogenic promoters during skeletal muscle differentiation. Pargyline 80-89 lysine (K)-specific demethylase 1A Mus musculus 40-44 20123967-6 2010 The importance of LSD1 function in neural stem cells was further supported by the observation that intracranial viral transduction of the LSD1 small interfering RNA (siRNA) or intraperitoneal injection of the LSD1 inhibitors pargyline and tranylcypromine led to dramatically reduced neural progenitor proliferation in the hippocampal dentate gyri of wild-type adult mouse brains. Pargyline 225-234 lysine (K)-specific demethylase 1A Mus musculus 18-22 20206139-5 2010 When co-incubated with MAOI pargyline, 5-MeO-DMT O-demethylation in 10 human liver microsomes showed significantly strong correlation with bufuralol 1"-hydroxylase activities (R(2)=0.98; P<0.0001) and CYP2D6 contents (R(2)=0.77; P=0.0007), whereas no appreciable correlations with enzymatic activities of other P450 enzymes. Pargyline 28-37 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 204-210 20123967-7 2010 However, knockout of TLX expression abolished the inhibitory effect of pargyline and tranylcypromine on neural progenitor proliferation, suggesting that TLX is critical for the LSD1 inhibitor effect. Pargyline 71-80 lysine (K)-specific demethylase 1A Mus musculus 177-181 19789505-3 2009 MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp. Pargyline 82-91 monoamine oxidase A Homo sapiens 106-111 21200377-7 2010 MAO-A was inhibited by the following drugs: pargyline > clorgyline > iproniazid > fluoxetine > desipramine > amitriptyline > imipramine > citalopram > venlafaxine > reboxetine > olanzapine > mirtazapine > tianeptine > moclobemide, cocaine >> lithium, valproate. Pargyline 44-53 monoamine oxidase A Sus scrofa 0-5 21200377-8 2010 MAO-B was inhibited by the following drugs: pargyline > clorgyline > iproniazid > fluoxetine > venlafaxine > amitriptyline > olanzapine > citalopram > desipramine > reboxetine > imipramine > tianeptine > mirtazapine, cocaine >> moclobemide, lithium, valproate. Pargyline 44-53 monoamine oxidase B Sus scrofa 0-5 19994847-7 2009 Additionally, the Bcl-2 antiapoptotic protein is predicted to bind pargyline, and the antiapoptic p53 interacting protein MDM2 is suggested to bind clofazimine. Pargyline 67-76 BCL2 apoptosis regulator Homo sapiens 18-23 19789505-3 2009 MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp. Pargyline 82-91 monoamine oxidase B Homo sapiens 113-118 19789505-3 2009 MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp. Pargyline 82-91 amine oxidase copper containing 2 Homo sapiens 124-128 19296688-0 2009 Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. Pargyline 28-37 monoamine oxidase A Homo sapiens 80-106 19559489-5 2009 The facilitating effects of pargyline on lymphocyte apoptosis were mimicked by activators of adenylate cyclase and PKC, but reversed by inhibitors of PKA, PLC and PKC. Pargyline 28-37 heparan sulfate proteoglycan 2 Homo sapiens 155-158 19542488-11 2009 When 10 microM 5-HT was used, an additional hypertrophic response, prevented by the MAO inhibitors pargyline and RO 41-1049, was observed. Pargyline 99-108 monoamine oxidase A Rattus norvegicus 84-87 17912044-3 2007 This study examined the effects of three MAOIs (phenelzine, clorgyline and pargyline) with varying selectivity for MAOA and MAOB in the nicotine drug discrimination procedure in rats. Pargyline 75-84 monoamine oxidase A Rattus norvegicus 115-119 18322152-4 2008 In rats treated with the monoamine oxidase-A (MAO-A) inhibitor pargyline to prevent 5-HT metabolism, basal 5-HT levels were higher in veins than in arteries. Pargyline 63-72 monoamine oxidase A Rattus norvegicus 25-44 18322152-4 2008 In rats treated with the monoamine oxidase-A (MAO-A) inhibitor pargyline to prevent 5-HT metabolism, basal 5-HT levels were higher in veins than in arteries. Pargyline 63-72 monoamine oxidase A Rattus norvegicus 46-51 18539478-5 2008 However, combined treatment of this lower dose of S with pargyline inhibited SSAO, MAO, energy intake, weight gain and fat deposition. Pargyline 57-66 amine oxidase, copper containing 3 Rattus norvegicus 77-81 18539478-5 2008 However, combined treatment of this lower dose of S with pargyline inhibited SSAO, MAO, energy intake, weight gain and fat deposition. Pargyline 57-66 monoamine oxidase A Rattus norvegicus 83-86 17977742-7 2007 P+S treatments abolished MAO and SSAO activities in any tested tissue. Pargyline 0-3 monoamine oxidase A Rattus norvegicus 25-28 17977742-7 2007 P+S treatments abolished MAO and SSAO activities in any tested tissue. Pargyline 0-3 amine oxidase, copper containing 3 Rattus norvegicus 33-37 17977742-11 2007 Although our results did not directly demonstrate that amines are able to spontaneously produce in vivo the insulin-like effects described in vitro, we propose that P+S-induced reduction of fat deposition results from decreased food intake and from impaired MAO- and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines. Pargyline 165-168 monoamine oxidase A Rattus norvegicus 258-261 17977742-11 2007 Although our results did not directly demonstrate that amines are able to spontaneously produce in vivo the insulin-like effects described in vitro, we propose that P+S-induced reduction of fat deposition results from decreased food intake and from impaired MAO- and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines. Pargyline 165-168 amine oxidase, copper containing 3 Rattus norvegicus 267-271 18198902-3 2008 A pargyline based nitroxide spin labeled irreversible inhibitor (ParSL) was used as a MAO active site specific spin probe to measure intersubunit distances in detergent (octyl beta-d-glucopyranoside, OGP) purified and OMM bound forms by a pulsed dipolar ESR spectroscopic (PDS) technique. Pargyline 2-11 oviductal glycoprotein 1 Homo sapiens 200-203 17912044-3 2007 This study examined the effects of three MAOIs (phenelzine, clorgyline and pargyline) with varying selectivity for MAOA and MAOB in the nicotine drug discrimination procedure in rats. Pargyline 75-84 monoamine oxidase B Rattus norvegicus 124-128 17760865-4 2007 Infusion of TRH into the 3vt increased histamine turnover as assessed by pargyline-induced accumulation of tele-methylhistamine (t-MH, a major metabolite of neuronal histamine in the brain) in the tuberomammillary nucleus (TMN), the paraventricular nucleus, and the ventromedial hypothalamic nucleus in rats. Pargyline 73-82 thyrotropin releasing hormone Rattus norvegicus 12-15 17561096-4 2007 Silencing MAO-A by siRNA, pharmacological MAO-A inhibitors (pargyline and Ro41-1049), and the antioxidant/ROS scavenger butylated hydroxytoluene (BHT) inhibited the signaling cascade, suggesting that ROS generated during tyramine oxidation by MAO-A are required. Pargyline 60-69 monoamine oxidase A Homo sapiens 10-15 17428504-11 2007 Pargyline may enhance BLM indirectly by preventing the depletion of oxygen by monoamine and polyamine oxidase. Pargyline 0-9 polyamine oxidase Saccharomyces cerevisiae S288C 92-109 17692830-4 2007 Intense dopamine immunoreactivity became visible in a large number of cells and axons (possibly containing AADC) with wide distribution in the brain following administration of L-DOPA with Pargyline. Pargyline 189-198 dopa decarboxylase Homo sapiens 107-111 16079795-8 2005 Furthermore, we identify pargyline as an inhibitor of LSD1. Pargyline 25-34 lysine demethylase 1A Homo sapiens 54-58 17400208-3 2007 The irreversible and non-selective MAO inhibitor pargyline, and the reversible and selective MAO-A inhibitor clorgyline, produced increases in 5-HT syndrome in the 5-HTP-treated rats, while subchronic co-administration of imipramine partly intensified and partly attenuated the syndrome, whereas milnacipran only attenuated the syndrome. Pargyline 49-58 monoamine oxidase A Rattus norvegicus 35-38 17303090-7 2007 During proestrus, pargyline stimulated nNOS activity at 9 h and inhibited it at 11 h. nNOS expression was inhibited by pargyline at 15 h. Depletion of 5-HT content in the MPOA increased LH secretion in ovariectomized rats treated with E(2) plus P(4), but it did not modify in rats treated with either oil or E(2). Pargyline 18-27 nitric oxide synthase 1 Rattus norvegicus 39-43 16754787-5 2006 In all of the 5-HT-uptake studies, we used arteries isolated from rats treated with the monoamine oxidase-A inhibitor pargyline to minimize 5-HT metabolism. Pargyline 118-127 monoamine oxidase A Rattus norvegicus 88-107 17030739-2 2006 The 3A resolution structure of recombinant human MAO-B originally determined was of the enzyme complexed with pargyline, an irreversible inhibitor covalently bound to the N5 atom of the flavin coenzyme. Pargyline 110-119 monoamine oxidase B Homo sapiens 49-54 16979412-6 2006 In addition, tyramine and benzylamine impaired tumor necrosis factor alpha-dependent nitric oxide formation in a pargyline- and semicarbazide-sensitive manner, respectively. Pargyline 113-122 tumor necrosis factor Mus musculus 47-74 15703274-7 2005 In contrast, they were extensively (>80%) prevented by the amine uptake inhibitor imipramine, the MAO inhibitor pargyline and the MEK inhibitor PD 98059. Pargyline 115-124 monoamine oxidase A Rattus norvegicus 101-104 15894564-6 2005 I3vt infusion of GLP-1 increased the CRH content and histamine turnover assessed using the pargyline-induced accumulation of tele-methyl histamine (t-MH), a major metabolite of neuronal histamine, in the hypothalamus. Pargyline 91-100 glucagon Rattus norvegicus 17-22 15864503-5 2005 Inhibition of MAO (pargyline 1 mM) significantly increased the basal content of DA and the percentage of the added non-metabolised DA (to 95+/-10%) in PCT but had no effect on MTAL or MCD. Pargyline 19-28 monoamine oxidase A Rattus norvegicus 14-17 15351283-5 2004 As expected, the brain level of PEA escalated to about 6-fold, while the 5-HIAA level remained unchanged following a dose of the MAO B inhibitor pargyline at 2mg/kg. Pargyline 145-154 monoamine oxidase B Rattus norvegicus 129-134 15279562-4 2004 The recent development of high level expression systems for producing recombinant human liver MAO A and MAO B in Pichia pastoris has facilitated the determination of the three dimensional crystal structures of MAO B (up to 1.7 angstroms resolution) in complex with different reversible (isatin, 1,4-diphenyl-2-butene) and irreversible inhibitors (pargyline, N-(2-aminoethyl)-p-chlorobenzamide, and trans-2-phenylcyclopropylamine). Pargyline 347-356 monoamine oxidase B Homo sapiens 210-215 12777388-7 2003 Cys5 and Cys266 were identified as the only residues modified by biotin-derivatized NEM in clorgyline-inactivated MAO A and pargyline-inactivated MAO B, respectively. Pargyline 124-133 monoamine oxidase B Homo sapiens 146-151 15167270-4 2004 5-HT and the metabolite 5-hydroxyindole acetic acid (5-HIAA) were detected in aorta, carotid, and superior mesenteric arteries using HPLC; the MAOA inhibitor pargyline significantly increased (over 400%) arterial 5-HT concentration. Pargyline 158-167 monoamine oxidase A Rattus norvegicus 143-147 15075350-4 2004 Pargyline and semicarbazide, specific inhibitors of MAO and SSAO, respectively, canceled this negative effect of MAO substrates on NOS2 expression. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 52-55 15075350-4 2004 Pargyline and semicarbazide, specific inhibitors of MAO and SSAO, respectively, canceled this negative effect of MAO substrates on NOS2 expression. Pargyline 0-9 amine oxidase, copper containing 3 Rattus norvegicus 60-64 15075350-4 2004 Pargyline and semicarbazide, specific inhibitors of MAO and SSAO, respectively, canceled this negative effect of MAO substrates on NOS2 expression. Pargyline 0-9 monoamine oxidase A Rattus norvegicus 113-116 15075350-4 2004 Pargyline and semicarbazide, specific inhibitors of MAO and SSAO, respectively, canceled this negative effect of MAO substrates on NOS2 expression. Pargyline 0-9 nitric oxide synthase 2 Rattus norvegicus 131-135 12777388-15 2003 This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes. Pargyline 104-113 monoamine oxidase A Homo sapiens 26-31 12777388-15 2003 This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes. Pargyline 104-113 monoamine oxidase B Homo sapiens 74-79 12777388-15 2003 This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes. Pargyline 104-113 monoamine oxidase A Homo sapiens 130-141 12091466-3 2002 Inhibition was prevented in the presence of pargyline and clorgyline demonstrating that mitochondrial inhibition arose from products formed following MAO metabolism and could include hydrogen peroxide (H(2) O(2) ), hydroxyl radical, oxidized glutathione (GSSG) or glutathione-protein mixed disulfides (PrSSG). Pargyline 44-53 monoamine oxidase A Rattus norvegicus 150-153 12618595-6 2003 After the intravenous co-administration of 5-MT (10 mg/kg) and pargyline (20 mg/kg), serum 5-HT level was about 3-fold higher in CYP2D6-transgenic mice than wild-type mice. Pargyline 63-72 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 129-135 12039844-5 2002 Rat pretreatment with the irreversible MAO inhibitor pargyline resulted in the following: i) prevented H2O2 production and lipid peroxidation; ii) decreased tubular cell apoptosis and necrosis, measured by TUNEL staining and histomorphological criteria; and iii) increased tubular cell proliferation as determined by proliferating cell nuclear antigen expression. Pargyline 53-62 monoamine oxidase A Rattus norvegicus 39-42 11179960-4 2001 Of the agmatine taken up, 10% is transformed into polyamines and 50% is transformed into 4-guanidinobutyrate, as demonstrated by HPLC and MS. Inhibition by aminoguanidine and pargyline shows that this is due to diamine oxidase and an aldehyde dehydrogenase. Pargyline 175-184 amine oxidase, copper containing 1 Rattus norvegicus 211-226 11682054-5 2001 Pargyline protected human lymphoma U937 cells against UVB-induced apoptosis, by reducing AO activity, mitochondrial uncoupling and cytochrome c release. Pargyline 0-9 cytochrome c, somatic Homo sapiens 131-143 11453370-10 2001 These results indicate that near total inhibition of MAO-A by clorgyline and pargyline as assessed by MAO activity measurement induces an increase in locomotor activity but that inhibition of MAO-A or MAO-B, either alone or combined, does not facilitate spatial learning in adult rats. Pargyline 77-86 monoamine oxidase A Rattus norvegicus 53-58 12172644-6 2002 The MAO inhibitors clorgyline (50 mM) and pargyline (500 mM) completely protect against MPT induction by 100 mM tyramine but also inhibit the phenomenon, although with different efficacy, when it is induced by 100 mM Ca2+ in the absence of tyramine. Pargyline 42-51 monoamine oxidase A Rattus norvegicus 4-7 12031549-7 2002 Treatments either with the antioxidant alpha-tocopherol acetate or the MAO inhibitor pargyline, given daily for 7 days after lesion, partially prevented the 40 microg MPP(+)-induced inhibition of DA uptake. Pargyline 85-94 monoamine oxidase A Rattus norvegicus 71-74 11753429-4 2002 The electron density shows that pargyline, an analog of the clinically used MAO B inhibitor, deprenyl, binds covalently to the flavin N5 atom. Pargyline 32-41 monoamine oxidase B Homo sapiens 76-81 11413237-2 2001 It was used to investigate the role of endogenous neurotensin in the regulation of dopamine efflux in the nucleus accumbens and striatum of anaesthetized and pargyline-treated rats. Pargyline 158-167 neurotensin Rattus norvegicus 50-61 10963750-8 2000 The stronger MAO-A inhibitors clorgyline or pargyline (both 10 microM) mimicked the moclobemide-effects. Pargyline 44-53 amine oxidase [flavin-containing] A Cavia porcellus 13-18 10996452-3 2000 A low dose of pargyline (10mg/kg) produced significantly higher inhibition of MAO-A in the alcoholised rats, whereas the degree of MAO-B inhibition was the same in both groups. Pargyline 14-23 monoamine oxidase A Rattus norvegicus 78-83 10996452-5 2000 Since chronic ethanol feeding reduced the content of reversible endogenous MAO inhibitor, tribulin, higher pargyline-induced inhibition of MAO-A in alcoholised rats may stem from a tribulin deficit. Pargyline 107-116 monoamine oxidase A Rattus norvegicus 75-78 10996452-5 2000 Since chronic ethanol feeding reduced the content of reversible endogenous MAO inhibitor, tribulin, higher pargyline-induced inhibition of MAO-A in alcoholised rats may stem from a tribulin deficit. Pargyline 107-116 monoamine oxidase A Rattus norvegicus 139-144 10719089-4 2000 Rats treated with intraperitoneal injections of pargyline, an MAO inhibitor, showed significantly stronger DA- and NA-staining intensities in LC neurons compared to normal rats. Pargyline 48-57 monoamine oxidase A Rattus norvegicus 62-65 10580415-3 1999 A bolus infusion of 1.0 microg leptin into the rat third cerebroventricle (i3vt) elevated the turnover rate of hypothalamic neuronal histamine (P < 0.05) as assessed by pargyline-induced accumulation of tele-methylhistamine (t-MH), a major metabolite of histamine. Pargyline 172-181 leptin Rattus norvegicus 31-37 11225512-2 2000 Administration of pargyline (10 mg/kg, s.c.) produced significantly higher inhibition of MAO-A in alcoholised rats, whereas MAO-B inhibition did not differ from that observed in control animals. Pargyline 18-27 monoamine oxidase A Rattus norvegicus 89-94 11225512-3 2000 The concentration-response curve for the inhibition of brain mitochondrial MAO-A and MAO-B by pargyline in vitro did not reveal higher sensitivity of MAO from alcoholised rats to pargyline. Pargyline 94-103 monoamine oxidase A Rattus norvegicus 75-80 11225512-3 2000 The concentration-response curve for the inhibition of brain mitochondrial MAO-A and MAO-B by pargyline in vitro did not reveal higher sensitivity of MAO from alcoholised rats to pargyline. Pargyline 94-103 monoamine oxidase B Rattus norvegicus 85-90 11225512-3 2000 The concentration-response curve for the inhibition of brain mitochondrial MAO-A and MAO-B by pargyline in vitro did not reveal higher sensitivity of MAO from alcoholised rats to pargyline. Pargyline 94-103 monoamine oxidase A Rattus norvegicus 75-78 10567696-7 1999 The reduction by MPTP but not MPDP(+) was completely prevented by pargyline, a type B monoamine oxidase (MAO-B) inhibitor, in the synaptosomes. Pargyline 66-75 monoamine oxidase B Rattus norvegicus 105-110